Document:

EX-10.1

 Exhibit 10.1 

Certain identified information marked with [***] has been excluded from the exhibit because it is both not 

material and is the type that the registrant treats as private or confidential. 

STANDBY EQUITY PURCHASE AGREEMENT 

THIS STANDBY EQUITY PURCHASE AGREEMENT (this “Agreement”) dated as of July 27, 2022 is made by and between YA
II PN, LTD., a Cayman Islands exempt limited partnership (the “Investor”), and BIOTE CORP., a company incorporated under the laws of the State of Delaware (the “Company”). 

WHEREAS, the parties desire that, upon the terms and subject to the conditions contained herein, the Company shall have the right to
issue and sell to the Investor, from time to time as provided herein, and the Investor shall purchase from the Company, up to 5,000,000 shares (the “Common Shares”) of the Company’s shares of Class A common stock, par
value $0.0001 per share (the “Common Stock”); and 
 WHEREAS, the offer and sale of the Common Shares issuable
hereunder will be made in reliance upon Section 4(a)(2) under the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder (the “Securities Act”), or upon such other exemption from the
registration requirements of the Securities Act as may be available with respect to any or all of the transactions to be made hereunder. 

NOW, THEREFORE, the parties hereto agree as follows: 

Article I. Certain Definitions 

Section 1.01    “Additional Shares” shall have the meaning set forth in Section 2.01(d)(ii). 

Section 1.02    “Adjusted Advance Amount” shall have the meaning set forth in Section 2.01(d)(i). 

Section 1.03    “Advance” shall mean any issuance and sale of Advance Shares from the Company to the Investor
pursuant to Article II hereof. 
 Section 1.04    “Advance Date” shall mean the 1st Trading Day after expiration of the applicable Pricing Period for each Advance. 

Section 1.05    “Advance Notice” shall mean a written notice in the form of Exhibit A attached hereto to the
Investor executed by an officer of the Company and setting forth the number of Advance Shares that the Company desires to issue and sell to the Investor. 

Section 1.06    “Advance Notice Date” shall mean each date the Company is deemed to have delivered (in accordance
with Section 2.01(b) of this Agreement) an Advance Notice to the Investor, subject to the terms of this Agreement. 

Section 1.07    “Advance Shares” shall mean the shares of Common Stock that the Company shall issue and sell to the
Investor pursuant to an Advance. 
 Section 1.08    “Affiliate” shall have the meaning set forth in
Section 3.07. 

 Section 1.09    “Agreement” shall have the meaning set forth in
the preamble of this Agreement. 
 Section 1.10    “Applicable Laws” shall mean all applicable laws, statutes,
rules, regulations, orders, executive orders, directives, policies, guidelines and codes having the force of law, whether local, national, or international, as amended from time to time, including without limitation (i) all applicable laws that
relate to money laundering, terrorist financing, financial record keeping and reporting, (ii) all applicable laws that relate to anti-bribery, anti-corruption, books and records and internal controls, including the United States Foreign Corrupt
Practices Act of 1977, and (iii) any Sanctions laws. 
 Section 1.11    “Black Out Period” shall have the
meaning set forth in Section 6.02 
 Section 1.12    “Closing” shall have the meaning set forth in
Section 2.02. 
 Section 1.13    “Commitment Amount” shall mean 5,000,000 Common Shares, provided
that, the Company shall not affect any sales under this Agreement and the Investor shall not have the obligation to purchase Common Shares under this Agreement to the extent (but only to the extent) that after giving effect to such purchase and
sale the aggregate number of Common Shares issued under this Agreement would exceed 19.9% of the voting power or number of shares of issued and outstanding Common Stock and Class V common stock, par value $0.0001 per share as of the date of
this Agreement (the “Exchange Cap”) provided further that, the Exchange Cap will not apply if (a) the Company’s stockholders have approved issuances in excess of the Exchange Cap in accordance with the rules of the
Principal Market or (b) the average price of all applicable sales of Common Shares hereunder (including the Commitment Shares) equals or exceeds $3.81 per share (which represents the lower of (i) the closing price of the Common Stock (as
reflected on Bloomberg L.P.) immediately preceding the date of this Agreement; or (ii) the average closing price of the Common Stock for the five Trading Days immediately preceding the date of this Agreement). 

Section 1.14    “Commitment Shares” shall have the meaning set forth in Section 13.04. 

Section 1.15    “Commitment Period” shall mean the period commencing on the date hereof and expiring upon the date
of termination of this Agreement in accordance with Section 11.02. 
 Section 1.16    “Common Shares” shall
have the meaning set forth in the recitals of this Agreement. 
 Section 1.17    “Common Stock” shall have the
meaning set forth in the recitals of this Agreement. 
 Section 1.18    “Company” shall have the meaning set forth
in the preamble of this Agreement. 
 Section 1.19    “Company Indemnitees” shall have the meaning set forth in
Section 5.02. 
 Section 1.20    “Condition Satisfaction Date” shall have the meaning set forth in
Section 7.01. 
 Section 1.21    [RESERVED.] 

Section 1.22    “DTC” shall have the meaning set forth in Section 2.02(b). 

  
 - 2 - 

 Section 1.23    “DWAC” shall have the meaning set forth in
Section 2.02(b). 
 Section 1.24    “Environmental Laws” shall have the meaning set forth in
Section 4.08. 
 Section 1.25    “Exchange Act” shall mean the U.S. Securities Exchange Act of 1934, as
amended, and the rules and regulations promulgated thereunder. 
 Section 1.26    “Exchange Cap” shall have the
meaning set forth in Section 1.13. 
 Section 1.27    “Excluded Day” shall have the meaning set forth in
Section 2.01(d)(i). 
 Section 1.28    “Hazardous Materials” shall have the meaning set forth in
Section 4.08. 
 Section 1.29    “Indemnified Liabilities” shall have the meaning set forth in
Section 5.01. 
 Section 1.30    “Investor” shall have the meaning set forth in the preamble of this
Agreement. 
 Section 1.31    “Investor Indemnitees” shall have the meaning set forth in Section 5.01. 

Section 1.32    “Market Price” shall mean the lowest daily VWAP of the Common Stock during the relevant Pricing
Period, other than the daily VWAP on any Excluded Days. 
 Section 1.33    “Material Adverse Effect” shall mean
any event, occurrence or condition that has had or would reasonably be expected to have (i) a material adverse effect on the legality, validity or enforceability of this Agreement or the transactions contemplated herein, (ii) a material
adverse effect on the results of operations, assets, business or condition (financial or otherwise) of the Company and its Subsidiaries, taken as a whole, or (iii) a material adverse effect on the Company’s ability to perform in any
material respect on a timely basis its obligations under this Agreement. 
 Section 1.34    “Material Outside
Event” shall have the meaning set forth in Section 6.08. 
 Section 1.35    “Maximum Advance Amount”
in respect of each Advance Notice means the greater of: (i) an amount equal to thirty percent (30%) of the aggregate volume traded during the five (5) Trading Days immediately preceding an Advance Notice, or (ii) 1,000,000 Common Shares.

 Section 1.36    “Minimum Acceptable Price” or “MAP” shall mean the minimum price notified by
the Company to the Investor in each Advance Notice, if applicable. 
 Section 1.37    “OFAC” shall have the
meaning set forth in Section 4.30. 
 Section 1.38    “Ownership Limitation” shall have the meaning set forth
in Section 2.01(c)(i). 
 Section 1.39    “Person” shall mean an individual, a corporation, a partnership, a
limited liability company, a trust or other entity or organization, including a government or political subdivision or an agency or instrumentality thereof. 

Section 1.40    “Plan of Distribution” shall mean the section of a Registration Statement disclosing the plan of
distribution of the Shares. 

  
 - 3 - 

 Section 1.41    “Pricing Period” shall mean the three
(3) consecutive Trading Days commencing on the Advance Notice Date. 
 Section 1.42    “Principal Market”
shall mean the Nasdaq Global Market; provided, however, that in the event the Common Stock are ever listed or traded on The New York Stock Exchange, NYSE American, the Nasdaq Global Select Market, the Nasdaq Capital Market, the OTCBB, the
Pink Open Market operated by OTC Markets Group, Inc., or the NYSE Euronext (or any successors to any of the foregoing), then the “Principal Market” shall mean such other market or exchange on which the Common Stock are then listed or
traded to the extent such other market or exchange is the principal trading exchange or market for the Common Stock. 

Section 1.43    “Prospectus” shall mean any prospectus (including, without limitation, all amendments and
supplements thereto) used by the Company in connection with a Registration Statement. 
 Section 1.44    “Prospectus
Supplement” shall mean any prospectus supplement to a Prospectus filed with the SEC pursuant to Rule 424(b) under the Securities Act, including, without limitation, any prospectus supplement to be filed in accordance with Section 6.01
hereof. 
 Section 1.45    “Purchase Price” shall mean the price per Advance Share obtained by multiplying the
Market Price by 97.0%. 
 Section 1.46    “Registrable Securities” shall mean (i) the Shares, and
(ii) any securities issued or issuable with respect to any of the foregoing by way of exchange, stock dividend or stock split or in connection with a combination of shares, recapitalization, merger, consolidation or other reorganization or
otherwise. 
 Section 1.47    “Registration Limitation” shall have the meaning set forth in
Section 2.01(c)(ii). 
 Section 1.48    “Registration Statement” shall mean a registration statement on Form S-1 or Form S-3 or on such other form promulgated by the SEC for which the Company then qualifies and which counsel for the Company shall deem appropriate, and which form
shall be available for the registration of the resale by the Investor of the Registrable Securities under the Securities Act, which registration statement provides for the resale from time to time of the Shares as provided herein. 

Section 1.49    “Regulation D” shall mean the provisions of Regulation D promulgated under the Securities Act. 

Section 1.50    “Sanctions” shall have the meaning set forth in Section 4.30. 

Section 1.51    [RESERVED.] 

Section 1.52    “SEC” shall mean the U.S. Securities and Exchange Commission. 

Section 1.53    “SEC Documents” shall have the meaning set forth in Section 4.05. 

Section 1.54    “Securities Act” shall have the meaning set forth in the recitals of this Agreement. 

  
 - 4 - 

 Section 1.55    “Settlement Document” shall have the meaning set
forth in Section 2.02(a). 
 Section 1.56    “Shares” shall mean the Commitment Shares and the Advance Shares
to be issued from time to time hereunder. 
 Section 1.57    “Subsidiaries” shall mean any Person in which the
Company, directly or indirectly, (x) owns a majority of the outstanding capital stock or holds a majority of the equity or similar interest of such Person or (y) controls or operates all or substantially all of the business, operations or
administration of such Person, and the foregoing are collectively referred to herein as “Subsidiaries.” 

Section 1.58    “Trading Day” shall mean any day during which the Principal Market shall be open for business. 

Section 1.59    “Transaction Documents” shall have the meaning set forth in Section 4.02. 

Section 1.60    “VWAP” shall mean for any Trading Day, the daily volume weighted average price of the Common Stock
for such Trading Day on the Principal Market during regular trading hours as reported by Bloomberg L.P. 
 Article II. Advances 

Section 2.01    Advances; Mechanics. Upon the terms, and subject to the conditions of this Agreement, during the Commitment
Period, the Company, at its sole and exclusive discretion, shall have the right, but not the obligation to issue and sell to the Investor, and the Investor shall purchase from the Company, Advance Shares by the delivery to the Investor of Advance
Notices on the following terms: 
  

	 	(a)	 Advance Notice. At any time during the Commitment Period the Company may require the Investor to
purchase Shares by delivering an Advance Notice to the Investor, subject to the satisfaction or waiver by the Investor of the conditions set forth in Section 7.01, and in accordance with the following provisions: 

 

	 	(i)	 The Company shall, in its sole discretion, select the number of Advance Shares, not to exceed the Maximum
Advance Amount, it desires to issue and sell to the Investor in each Advance Notice and the time it desires to deliver each Advance Notice. 

  

	 	(ii)	 There shall be no mandatory minimum Advances and no non-usages fee for
not utilizing the Commitment Amount or any part thereof. 

  

	 	(b)	 Date of Delivery of Advance Notice. Advance Notices shall be delivered in accordance with the
instructions set forth on the bottom of Exhibit A. An Advance Notice shall be deemed delivered on (i) the day it is received by the Investor if such notice is received by email prior on or before 8:30 a.m. Eastern Time (or later if
waived by the Investor in its sole discretion) in accordance with the instructions set forth on the bottom of Exhibit A, or (ii) the immediately succeeding day if it is received by email after 8:30 a.m. Eastern Time, in each case in accordance
with the instructions set forth on the bottom of Exhibit A. 

  
 - 5 - 

	 	(c)	 Advance Limitations. Regardless of the number of Advance Shares requested by the Company in the Advance
Notice, the final number of Advance Shares to be issued and sold pursuant to an Advance Notice shall be reduced in accordance with each of the following limitations: 

 

	 	(i)	 Ownership Limitation; Commitment Amount. In no event shall the number of Advance Shares issuable to the
Investor pursuant to an Advance cause the aggregate number of shares of Common Stock beneficially owned (as calculated pursuant to Section 13(d) of the Exchange Act) by the Investor and its Affiliates (on an aggregated basis) to exceed 4.99% of
the then outstanding Common Stock (the “Ownership Limitation”). In connection with each Advance Notice delivered by the Company, any portion of an Advance that would (i) cause the Investor to exceed the Ownership Limitation or
(ii) cause the aggregate number of Shares issued and sold to the Investor hereunder to exceed the Commitment Amount shall automatically be withdrawn with no further action required by the Company, and such Advance Notice shall be deemed
automatically modified to reduce the number of Advance Shares requested by an amount equal to such withdrawn portion; provided that in the event of any such automatic withdrawal and automatic modification, Investor will promptly notify the Company
of such event. 

  

	 	(ii)	 Registration Limitation and Exchange Cap. In no event shall an Advance exceed the amount registered
under the Registration Statement then in effect (the “Registration Limitation”) or the Exchange Cap, to the extent applicable. In connection with each Advance Notice, any portion of an Advance that would exceed the Registration
Limitation or the Exchange Cap shall automatically be withdrawn with no further action required by the Company and such Advance Notice shall be deemed automatically modified to reduce the aggregate amount of the requested Advance by an amount equal
to such withdrawn portion in respect of each Advance Notice; provided that in the event of any such automatic withdrawal and automatic modification, Investor will promptly notify the Company of such event. 

 

	 	(d)    Minimum	 Acceptable Price. 

 

	 	(i)	 With respect to each Advance Notice, the Company may notify the Investor of the MAP with respect to such
Advance by indicating a MAP on such Advance Notice. If no MAP is specified in an Advance Notice, then no MAP shall be in effect in connection with such Advance. Each Trading Day during a Pricing Period for which (A) with respect to each Advance
Notice with a MAP, the VWAP of the Common Stock is below the Minimum Acceptable Price in effect with respect to such Advance Notice, or (B) there is no VWAP (each such day, an “Excluded Day”), shall result in an

  
 - 6 - 

	 	
automatic reduction to the number of Advance Shares set forth in such Advance Notice by one-third (the resulting amount of each Advance being the
“Adjusted Advance Amount”), and each Excluded Day shall be excluded from the Pricing Period for purposes of determining the Market Price. 

  

	 	(ii)	 The total Advance Shares in respect of each Advance (after reductions have been made to arrive at the Adjusted
Advance Amount) shall be automatically increased by such number of Common Shares (the “Additional Shares”) equal to the number of Common Shares sold by the Investor on such Excluded Day, if any, and the price paid per share for each
Additional Share shall be equal to the MAP in effect with respect to such Advance Notice (without any further discount), provided that this increase shall not cause the total Advance Shares to exceed the amount set forth in the original Advance
Notice or any limitations set forth in Section 2.01(c). 

  

	 	(e)	 Unconditional Contract. Notwithstanding any other provision in this Agreement, the Company and the
Investor acknowledge and agree that upon the Investor’s receipt of a valid Advance Notice the parties shall be deemed to have entered into an unconditional contract binding on both parties for the purchase and sale of Advance Shares pursuant to
such Advance Notice in accordance with the terms of this Agreement and (i) subject to Applicable Law and (ii) subject to Section 3.08 (Trading Activities), the Investor may sell Common Shares during the applicable Pricing Period.

 Section 2.02    Closings. The closing of each Advance and each sale and purchase of Advance Shares
(each, a “Closing”) shall take place as soon as practicable on or after each Advance Date in accordance with the procedures set forth below. The parties acknowledge that the Purchase Price is not known at the time the Advance Notice
is delivered (at which time the Investor is irrevocably bound) but shall be determined on each Closing based on the daily prices of the Common Stock that are the inputs to the determination of the Purchase Price as set forth further below. In
connection with each Closing, the Company and the Investor shall fulfill each of its obligations as set forth below: 
  

	 	(a)	 On each Advance Date, the Investor shall deliver to the Company a written document, in the form attached hereto
as Exhibit B (each a “Settlement Document”), setting forth the final number of Shares to be purchased by the Investor (taking into account any adjustments pursuant to Section 2.01), the Market Price, the
Purchase Price, the aggregate proceeds to be paid by the Investor to the Company, and a report by Bloomberg, L.P. indicating the VWAP for each of the Trading Days during the applicable Pricing Period, in each case in accordance with the terms and
conditions of this Agreement. 

  

	 	(b)	 Promptly after receipt of the Settlement Document with respect to each Advance (and, in any event, not later
than two Trading Days after such receipt), the Company will, or will cause its transfer agent to, electronically transfer such number of Advance Shares purchased by the Investor (as set forth in the Settlement Document) by crediting the
Investor’s account or its designee’s account at the Depository Trust Company (“DTC”) through its Deposit Withdrawal at Custodian System (“DWAC”) or by such other means

  
 - 7 - 

	 	
of delivery as may be mutually agreed upon by the parties hereto, and transmit notification to the Investor that such share transfer has been requested. Promptly upon receipt of such
notification, the Investor shall pay to the Company the aggregate purchase price of the Shares (as set forth in the Settlement Document) in cash in immediately available funds to an account designated by the Company in writing and transmit
notification to the Company that such funds transfer has been requested. No fractional shares shall be issued, and any fractional amounts shall be rounded to the next higher whole number of shares. To facilitate the transfer of the Common Shares by
the Investor, the Common Shares will not bear any restrictive legends so long as there is an effective Registration Statement covering the resale of such Common Shares (it being understood and agreed by the Investor that notwithstanding the lack of
restrictive legends, the Investor may only sell such Common Shares pursuant to the Plan of Distribution set forth in the Prospectus included in the Registration Statement and otherwise in compliance with the requirements of the Securities Act
(including any applicable prospectus delivery requirements) or pursuant to an available exemption). 

  

	 	(c)	 Notwithstanding Section 2.02(b), the certificate(s) or book-entry statement(s) representing the Commitment
Shares issued prior to the date the Registration Statement is declared effective by the SEC shall bear a restrictive legend in substantially the following form (and stop transfer instructions may be placed against transfer of the Commitment Shares):

 THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE
“SECURITIES ACT”), OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES REPRESENTED HEREBY HAVE BEEN SOLD IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT AND SUCH STATE SECURITIES LAWS AND, ACCORDINGLY, MAY NOT BE
OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE
WITH APPLICABLE STATE SECURITIES LAWS 
  

	 	(d)	 On or prior to the Advance Date, each of the Company and the Investor shall deliver to the other all documents,
instruments and writings expressly required to be delivered by either of them pursuant to this Agreement in order to implement and effect the transactions contemplated herein. 

 

	 	(e)	 On or prior to the first Closing, the Investor shall deliver to the Company a duly executed IRS Form W-8BEN-E, IRS Form W-8IMY (with all relevant attachments), or other applicable IRS Form W-8 or W-9, and any other similar Tax documentation reasonably requested by the Company. Investor shall update any such form or certification (or any applicable successor form) promptly upon the obsolescence or invalidity
of any form previously delivered by such Investor. 

  

	 	(f)	 Notwithstanding anything to the contrary in this Agreement, if on any day during the applicable Pricing Period
(i) the Company notifies Investor that a Material Outside Event 

  
 - 8 - 

	 	
has occurred, or (ii) the Company notifies the Investor of a Black Out Period, the parties agree that the pending Advance shall end and the final number of Advance Shares to be purchased by
the Investor at the Closing for such Advance shall be equal to the number of Common Shares sold by the Investor during the applicable Pricing Period prior to the notification from the Company of a Material Outside Event or Black Out Period.

 Section 2.03    Hardship. 
  

	 	(a)	 In the event the Investor sells Common Shares of the Company after receipt of an Advance Notice and the Company
fails to perform its obligations as mandated in Section 2.02, the Company agrees that in addition to and in no way limiting the rights and obligations set forth in Article V hereto and in addition to any other remedy to which the Investor is
entitled at law or in equity, including, without limitation, specific performance, it will hold the Investor harmless against any loss, claim, damage, or expense (including reasonable legal fees and expenses), as incurred, arising out of or in
connection with such default by the Company and acknowledges that irreparable damage may occur in the event of any such default. It is accordingly agreed that the Investor shall be entitled to an injunction or injunctions to prevent such breaches of
this Agreement and to specifically enforce (subject to the Securities Act and other rules of the Principal Market), without the posting of a bond or other security, the terms and provisions of this Agreement. 

 

	 	(b)	 In the event the Company provides an Advance Notice and the Investor fails to perform its obligations as
mandated in Section 2.02, the Investor agrees that in addition to and in no way limiting the rights and obligations set forth in Article V hereto and in addition to any other remedy to which the Company is entitled at law or in equity,
including, without limitation, specific performance, it will hold the Company harmless against any loss, claim, damage, or expense (including reasonable legal fees and expenses), as incurred, arising out of or in connection with such default by the
Investor and acknowledges that irreparable damage may occur in the event of any such default. It is accordingly agreed that the Company shall be entitled to an injunction or injunctions to prevent such breaches of this Agreement and to specifically
enforce (subject to the Securities Act and other rules of the Principal Market), without the posting of a bond or other security, the terms and provisions of this Agreement. 

Section 2.04    Completion of Resale Pursuant to the Registration Statement. After the Investor has purchased the full
Commitment Amount and has completed the subsequent resale of the full Commitment Amount pursuant to the Registration Statement, Investor will notify the Company that all subsequent resales are completed and the Company will be under no further
obligation to maintain the effectiveness of the Registration Statement. The Company also shall have no further obligation to maintain the effectiveness of the Registration Statement after the 180th day following the earlier to occur of the latest
Closing that has occurred or the termination of this Agreement in accordance with its terms. 
 Section 2.05    Pre-Advance Loans. Subject to the mutual consent of the parties, from time to time, the Company may request, and the Investor shall provide, a pre-advance loan from the
Investor, pursuant to a promissory note, on terms and conditions to be agreed by the parties. 

  
 - 9 - 

 Article III. Representations and Warranties of Investor 

The Investor represents, warrants to and agrees with the Company that the following are true and correct as of the date hereof and as of each
Advance Notice Date and each Advance Date that: 
 Section 3.01    Organization and Authorization. The Investor is duly
organized, validly existing and in good standing under the laws of the Cayman Islands and has all requisite power and authority to execute, deliver and perform this Agreement, including all transactions contemplated hereby. The decision to invest
and the execution and delivery of this Agreement by the Investor, the performance by the Investor of its obligations hereunder and the consummation by the Investor of the transactions contemplated hereby have been duly authorized and require no
other proceedings on the part of the Investor. The undersigned has the right, power and authority to execute and deliver this Agreement and all other instruments on behalf of the Investor or its shareholders. This Agreement has been duly executed
and delivered by the Investor and, assuming the execution and delivery hereof and acceptance thereof by the Company, will constitute the legal, valid and binding obligations of the Investor, enforceable against the Investor in accordance with its
terms. 
 Section 3.02    Evaluation of Risks. The Investor has such knowledge and experience in financial, tax and business
matters as to be capable of evaluating the merits and risks of, and bearing the economic risks entailed by, an investment in the Common Shares of the Company and of protecting its interests in connection with the transactions contemplated hereby.
The Investor, either alone or together with its representatives, has such knowledge, sophistication and experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment in the Common
Shares, and has so evaluated the merits and risks of such investment. The Investor acknowledges and agrees that its investment in the Company involves a high degree of risk, and that the Investor may lose all or a part of its investment. 

Section 3.03    No Legal, Investment or Tax Advice from the Company. The Investor acknowledges that it had the opportunity to
review this Agreement and the transactions contemplated by this Agreement with its own legal counsel and investment and tax advisors. The Investor is relying solely on such counsel and advisors and not on any statements or representations of the
Company or any of the Company’s representatives or agents for legal, tax, investment or other advice with respect to the Investor’s acquisition of Common Shares hereunder, the transactions contemplated by this Agreement or the laws of any
jurisdiction, and the Investor acknowledges that the Investor may lose all or a part of its investment. 

Section 3.04    Investment Purpose. The Investor is acquiring the Common Shares for its own account, for investment purposes
and not with a view towards, or for resale in connection with, the public sale or distribution thereof, except pursuant to sales registered under or exempt from the registration requirements of the Securities Act; provided, however, that
by making the representations herein, the Investor does not agree, or make any representation or warranty, to hold any of the Shares for any minimum or other specific term and reserves the right to dispose of the Shares at any time in accordance
with, or pursuant to, a Registration Statement filed pursuant to this Agreement or an applicable exemption under the Securities Act. The Investor does not presently have any agreement or understanding, directly or indirectly, with any Person to sell
or 

  
 - 10 - 

 
distribute any of the Shares. The Investor is acquiring the Shares hereunder in the ordinary course of its business. The Investor acknowledges that it will be disclosed as an
“underwriter” and a “selling stockholder” in each Registration Statement and in any prospectus contained therein. 

Section 3.05    Investor Status. The Investor is an institutional “accredited investor” as defined in Rule
501(a)(3) of Regulation D under the Securities Act and a “qualified institutional buyer” as defined in Rule 144A under the Securities Act. 

Section 3.06    Information. The Investor and its advisors (and its counsel), if any, have been furnished with all materials
relating to the business, finances and operations of the Company and information the Investor deemed material to making an informed investment decision. The Investor and its advisors (and its counsel), if any, have been afforded the opportunity to
ask questions of the Company and its management and have received answers to such questions. Neither such inquiries nor any other due diligence investigations conducted by such Investor or its advisors (and its counsel), if any, or its
representatives shall modify, amend or affect the Investor’s right to rely on the Company’s representations and warranties contained in this Agreement. The Investor acknowledges and agrees that the Company has not made to the Investor, and
the Investor acknowledges and agrees it has not relied upon, any representations and warranties of the Company, its employees or any third party other than the representations and warranties of the Company contained in this Agreement. The Investor
understands that its investment involves a high degree of risk. The Investor has sought such accounting, legal and tax advice, as it has considered necessary to make an informed investment decision with respect to the transactions contemplated
hereby. 
 Section 3.07    Not an Affiliate. The Investor is not an officer, director or a person that directly, or
indirectly through one or more intermediaries, controls or is controlled by, or is under common control with the Company or any “affiliate” of the Company (as that term is defined in Rule 405 promulgated under the Securities Act).

 Section 3.08    No Prior Short Sales. At no time prior to the date of this Agreement has the Investor, its sole member,
any of their respective officers or any entity managed or controlled by the Investor or its sole member engaged in or effected, in any manner whatsoever, directly or indirectly, for its own principal account, any (i) “short sale” (as such
term is defined in Rule 200 of Regulation SHO of the Exchange Act) of the Class A Common Stock or (ii) hedging transaction, which establishes a net short position with respect to the Class A Common Stock that remains in effect as of
the date of this Agreement. 
 Section 3.09    General Solicitation. Neither the Investor, nor any of its affiliates, nor
any person acting on its or their behalf, has engaged or will engage in any form of general solicitation or general advertising (within the meaning of Regulation D) in connection with any offer or sale of the Common Shares by the Investor. 

Section 3.10    Trading Activities. The Investor’s trading activities with respect to the Common Stock shall be in
compliance with all applicable federal and state securities laws, rules and regulations and the rules and regulations of the Principal Market. Neither the Investor nor its affiliates has any open short position in the Common Stock, and the Investor
agrees that it shall not, and that it will cause its affiliates not to, engage in any short sales with respect to the Common 

  
 - 11 - 

 
Stock; provided that the Company acknowledges and agrees that (a) the Investor may engage in the trading of options with respect to the Common Stock, (b) upon receipt of an Advance
Notice the Investor has the right to sell (i) the Shares to be issued to the Investor pursuant to the Advance Notice prior to receiving such Shares, or (ii) other shares of Common Stock sold by the Company to Investor pursuant to this
Agreement and which the Company has continuously held as a long position. 
 Article IV. Representations and Warranties of the Company

 Except as set forth in the SEC Documents, the Company represents and warrants to the Investor, as of the date hereof, each Advance
Notice Date and each Advance Date (other than representations and warranties which address matters only as of a certain date, which shall be true and correct as written as of such certain date), that: 

Section 4.01    Organization and Qualification. Each of the Company and its Subsidiaries (as defined below) is an entity duly
organized and validly existing under the laws of its state of organization or incorporation, and has the requisite power and authority to own its properties and to carry on its business as now being conducted. Each of the Company and its
Subsidiaries is duly qualified to do business and is in good standing (to the extent applicable) in every jurisdiction in which the nature of the business conducted by it makes such qualification necessary, except to the extent that the failure to
be so qualified or be in good standing would not have a Material Adverse Effect. 
 Section 4.02    Authorization, Enforcement,
Compliance with Other Instruments. The Company has the requisite corporate power and authority to enter into and perform its obligations under this Agreement and the other Transaction Documents and to issue the Shares in accordance with the
terms hereof and thereof. The execution and delivery by the Company of this Agreement and the other Transaction Documents, and the consummation by the Company of the transactions contemplated hereby and thereby (including, without limitation, the
issuance of the Common Shares) have been or (with respect to consummation) will be duly authorized by the Company’s board of directors and no further consent or authorization will be required by the Company, its board of directors or its
shareholders. This Agreement and the other Transaction Documents to which it is a party have been (or, when executed and delivered, will be) duly executed and delivered by the Company and, assuming the execution and delivery thereof and acceptance
by the Investor, constitute (or, when duly executed and delivered, will be) the legal, valid and binding obligations of the Company, enforceable against the Company in accordance with their respective terms, except as such enforceability may be
limited by general principles of equity or applicable bankruptcy, insolvency, reorganization, moratorium, liquidation or other laws relating to, or affecting generally, the enforcement of applicable creditors’ rights and remedies and except as
rights to indemnification and to contribution may be limited by federal or state securities law. “Transaction Documents” means, collectively, this Agreement and each of the other agreements and instruments entered into or delivered
by any of the parties hereto in connection with the transactions contemplated hereby and thereby, as may be amended from time to time. 

Section 4.03    Authorization of the Shares. The Shares to be issued under this Agreement have been, or with respect to Shares
to be purchased by the Investor pursuant to an Advance Notice, will be, when issued and delivered pursuant to the terms approved by the board of directors of the 

  
 - 12 - 

 
Company or a duly authorized committee thereof, or a duly authorized executive committee, against payment therefor as provided herein, duly and validly authorized and issued and fully paid and
nonassessable, free and clear of any pledge, lien, encumbrance, security interest or other claim, including any statutory or contractual preemptive rights, resale rights, rights of first refusal or other similar rights, and will be registered
pursuant to Section 12 of the Exchange Act. The Shares, when issued, will conform to the description thereof set forth in or incorporated into the Prospectus. 

Section 4.04    No Conflict. The execution, delivery and performance of the Transaction Documents by the Company and the
consummation by the Company of the transactions contemplated hereby and thereby (including, without limitation, the issuance of the Common Shares) will not (i) result in a violation of the articles of incorporation or other organizational
documents of the Company or its Subsidiaries (with respect to consummation, as the same may be amended prior to the date on which any of the transactions contemplated hereby are consummated), (ii) conflict with, or constitute a default (or an event
which with notice or lapse of time or both would become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture or instrument to which the Company or its Subsidiaries is a
party, or (iii) result in a violation of any law, rule, regulation, order, judgment or decree (including federal and state securities laws and regulations) applicable to the Company or its Subsidiaries or by which any property or asset of the
Company or its Subsidiaries is bound or affected except, in the case of clause (ii) or (iii) above, to the extent such violations that would not reasonably be expected to have a Material Adverse Effect. 

Section 4.05    SEC Documents; Financial Statements. The Company has timely filed (giving effect to permissible extensions in
accordance with Rule 12b-25 under the Exchange Act) all reports, schedules, forms, statements and other documents required to be filed by it with the SEC pursuant to the Exchange Act for the two years
preceding the date hereof (or such shorter period as the Company was required by law or regulation to file such material) (all of the foregoing filed within two years preceding the date hereof or amended after the date hereof, or filed after the
date hereof, and all exhibits included therein and financial statements and schedules thereto and documents incorporated by reference therein, and all registration statements filed by the Company under the Securities Act (including any Registration
statements filed hereunder), being hereinafter referred to as the “SEC Documents”). The Company has delivered or made available to the Investor through the SEC’s website at http://www.sec.gov, true and complete copies of the
SEC Documents. 
 Section 4.06    Financial Statements. The consolidated financial statements of the Company included or
incorporated by reference in SEC Documents, together with the related notes and schedules, present fairly, in all material respects, the consolidated financial position of the Company and the Subsidiaries as of the dates indicated and the
consolidated results of operations, cash flows and changes in stockholders’ equity of the Company for the periods specified and have been prepared in compliance with the requirements of the Securities Act and Exchange Act and in conformity with
generally accepted accounting principles in the United States (“GAAP”) applied on a consistent basis (except for (i) such adjustments to accounting standards and practices as are noted therein, (ii) in the case of unaudited
interim financial statements, to the extent such financial statements may not include footnotes required by GAAP or may be condensed or summary statements and (iii) such adjustments which will not be material, either individually or in the

  
 - 13 - 

 
aggregate) during the periods involved; the other financial and statistical data with respect to the Company and the Subsidiaries (as defined below) contained or incorporated by reference in the
SEC Documents are accurately and fairly presented and prepared on a basis consistent with the financial statements and books and records of the Company; there are no financial statements (historical or pro forma) that are required to be included or
incorporated by reference in the SEC Documents that are not included or incorporated by reference as required; the Company and the Subsidiaries (as defined below) do not have any material liabilities or obligations, direct or contingent (including
any off-balance sheet obligations), not described in the SEC Documents (excluding the exhibits thereto); and all disclosures contained or incorporated by reference in the SEC Documents regarding “non-GAAP financial measures” (as such term is defined by the rules and regulations of the Commission) comply in all material respects with Regulation G of the Exchange Act and Item 10 of Regulation S-K under the Securities Act, to the extent applicable. The interactive data in eXtensible Business Reporting Language included or incorporated by reference in the SEC Documents fairly presents the information
called for in all material respects and has been prepared in accordance with the SEC’s rules and guidelines applicable thereto. 

Section 4.07    Registration Statement and Prospectus. The Company and the transactions contemplated by this Agreement meet
the requirements for and comply with the conditions for the use of Form S-1 under the Securities Act. Each Registration Statement and the offer and sale of Shares as contemplated hereby meet the requirements
of Rule 415 under the Securities Act and comply in all material respects with said Rule. Any statutes, regulations, contracts or other documents that are required to be described in a Registration Statement or a Prospectus, or to be filed as
exhibits to a Registration Statement have been so described or filed. Copies of each Registration Statement, any Prospectus, and any such amendments or supplements and all documents incorporated by reference therein that were filed with the
Commission on or prior to the date of this Agreement have been delivered, or are available through EDGAR, to the Investor and its counsel. The Company has not distributed and, prior to the later to occur of each Settlement Date and completion of the
distribution of the Shares, will not distribute any offering material in connection with the offering or sale of the Shares other than a Registration Statement and the Prospectus and any Issuer Free Writing Prospectus (as defined below) to which the
Investor has consented. 
 Section 4.08    No Misstatement or Omission. Each Registration Statement, when it became or
becomes effective, and any Prospectus, on the date of such Prospectus or amendment or supplement, conformed and will conform in all material respects with the requirements of the Securities Act. At each Advance Date, the Registration Statement, and
the Prospectus, as of such date, will conform in all material respects with the requirements of the Securities Act. Each Registration Statement, when it became or becomes effective, did not, and will not, contain an untrue statement of a material
fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading. Each Prospectus did not, or will not, include an untrue statement of a material fact or omit to state a material fact
necessary to make the statements therein, in light of the circumstances under which they were made, not misleading. The documents incorporated by reference in a Prospectus or any Prospectus Supplement did not, and any further documents filed and
incorporated by reference therein will not, when filed with the Commission, contain an untrue statement of a material fact or omit to state a material fact required to be stated in such document or necessary to make the statements in such document,
in light of 

  
 - 14 - 

 
the circumstances under which they were made, not misleading. The foregoing shall not apply to statements in, or omissions from, any such document made in reliance upon, and in conformity with,
information furnished to the Company by the Investor specifically for use in the preparation thereof. 

Section 4.09    Conformity with Securities Act and Exchange Act. Each Registration Statement, each Prospectus, any Issuer Free
Writing Prospectus or any amendment or supplement thereto, and the documents incorporated by reference in each Registration Statement, Prospectus or any amendment or supplement thereto, when such documents were or are filed with the SEC under the
Securities Act or the Exchange Act or became or become effective under the Securities Act, as the case may be, conformed or will conform in all material respects with the requirements of the Securities Act and the Exchange Act, as applicable.

Section 4.10    Equity Capitalization. As of the date hereof, the authorized capital of the Company consists of 718,000,000
shares of capital stock, each with a par value of $0.0001, of which 600,000,000 shares are designated as Class A Common Stock, 8,000,000 shares are designated as Class B common stock (the “Class B Common
Stock”), 100,000,000shares are designated as Class V common stock (the “Class V Common Stock”), and 10,000,000 shares are preferred stock (the “Preferred Stock”). As of the date
hereof, the Company had 9,161,771 shares of Class A Common Stock, no shares of Class B Common Stock outstanding, 58,565,824 shares of Class V Common Stock and no shares of Preferred Stock outstanding. 

The Class A Common Stock is registered pursuant to Section 12(b) of the Exchange Act and is currently listed on a Principal Market
under the trading symbol “BTMD.” Except as disclosed in the SEC Documents, the Company has taken no action designed to, or likely to have the effect of, terminating the registration of the Common Stock under the Exchange Act, delisting the
Common Stock from the Principal Market. 
 Section 4.11    Intellectual Property Rights. The Company and its Subsidiaries
own or possess adequate rights or licenses to use all material trademarks, trade names, service marks, service mark registrations, service names, patents, patent rights, copyrights, inventions, licenses, approvals, governmental authorizations, trade
secrets and rights, if any, necessary to conduct their respective businesses as now conducted, except as would not cause a Material Adverse Effect. The Company and its Subsidiaries have not received written notice of any infringement by the Company
or its Subsidiaries of trademark, trade name rights, patents, patent rights, copyrights, inventions, licenses, service names, service marks, service mark registrations, or trade secrets, except as would not cause a Material Adverse Effect. To the
knowledge of the Company, there is no claim, action or proceeding being made or brought against, or to the Company’s knowledge, being threatened against the Company or its Subsidiaries regarding trademark, trade name, patents, patent rights,
invention, copyright, license, service names, service marks, service mark registrations, trade secret or other infringement, except as would not cause a Material Adverse Effect. 

Section 4.12    Employee Relations. Neither the Company nor any of its Subsidiaries is involved in any labor dispute nor, to
the knowledge of the Company or any of its Subsidiaries, has any such dispute been threatened in writing, in each case which is reasonably likely to cause a Material Adverse Effect. 

  
 - 15 - 

 Section 4.13    Environmental Laws. The Company and its Subsidiaries
(i) have not received written notice alleging any failure to comply in all material respects with all Environmental Laws (as defined below), (ii) have received all permits, licenses or other approvals required of them under applicable
Environmental Laws to conduct their respective businesses and (iii) have not received written notice alleging any failure to comply with all terms and conditions of any such permit, license or approval where, in each of the foregoing clauses
(i), (ii) and (iii), the failure to so comply would be reasonably expected to have, individually or in the aggregate, a Material Adverse Effect. The term “Environmental Laws” means all applicable federal, state and local laws
relating to pollution or protection of human health or the environment (including, without limitation, ambient air, surface water, groundwater, land surface or subsurface strata), including, without limitation, laws relating to emissions,
discharges, releases or threatened releases of chemicals, pollutants, contaminants, or toxic or hazardous substances or wastes (collectively, “Hazardous Materials”) into the environment, or otherwise relating to the manufacture,
processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials, as well as all authorizations, codes, decrees, demands or demand letters, injunctions, judgments, licenses, notices or notice letters, orders,
permits, plans or regulations issued, entered, promulgated or approved thereunder. 
 Section 4.14    Title. Except as would
not cause a Material Adverse Effect, the Company (or its Subsidiaries) has indefeasible fee simple or leasehold title to its properties and material assets owned by it, free and clear of any pledge, lien, security interest, encumbrance, claim or
equitable interest other than such as are not material to the business of the Company. Any real property and facilities held under lease by the Company and its Subsidiaries are held by them under valid, subsisting and enforceable leases with such
exceptions as are not material and do not interfere with the use made and proposed to be made of such property and buildings by the Company and its Subsidiaries. 

Section 4.15    Insurance. The Company and each of its Subsidiaries are insured by insurers of recognized financial
responsibility against such losses and risks and in such amounts as management of the Company believes to be prudent and customary in the businesses in which the Company and its Subsidiaries are engaged. The Company has no reason to believe that it
will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue its business at a cost that would not have a Material Adverse Effect.

 Section 4.16    Regulatory Permits. Except as would not cause a Material Adverse Effect, the Company and its Subsidiaries
possess all material certificates, authorizations and permits issued by the appropriate federal, state or foreign regulatory authorities necessary to own their respective businesses, and neither the Company nor any such Subsidiary has received any
written notice of proceedings relating to the revocation or modification of any such certificate, authorization or permits. 

Section 4.17    Internal Accounting Controls. The Company maintains a system of internal accounting controls sufficient to
provide reasonable assurance that (i) transactions are executed in accordance with management’s general or specific authorizations, (ii) transactions are recorded as necessary to permit preparation of financial statements in
conformity with generally accepted accounting principles and to maintain asset accountability, (iii) access to assets is permitted only 

  
 - 16 - 

 
in accordance with management’s general or specific authorization and (iv) the recorded accountability for assets is compared with the existing assets at reasonable intervals and
appropriate action is taken with respect to any differences. 
 Section 4.18    Absence of Litigation. Except as set forth
in Exhibit C hereto, there is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending against or affecting the Company, the Common Stock or
any of the Company’s Subsidiaries, wherein an unfavorable decision, ruling or finding could have a Material Adverse Effect. 

Section 4.19    Subsidiaries. Except as disclosed in the SEC Documents, the Company does not presently own or control,
directly or indirectly, any interest in any other corporation, partnership, association or other business entity. 

Section 4.20    Tax Matters. Except as would not cause a Material Adverse Effect, each of the Company and its Subsidiaries
(i) has timely filed all foreign, federal and state income and all other tax returns, reports and declarations required to be filed by any jurisdiction to which it is subject, (ii) has timely paid all taxes and other governmental
assessments and charges shown to be due on such returns, reports and declarations, except those being contested in good faith and (iii) has set aside on its books provision reasonably adequate for the payment of all taxes for periods subsequent
to the periods to which such returns, reports or declarations apply. The Company has not received written notification any unpaid taxes in any material amount claimed to be due by the taxing authority of any jurisdiction, and the officers of the
Company and its Subsidiaries know of no basis for any such claim where failure to pay would cause a Material Adverse Effect. 

Section 4.21    Certain Transactions. Except as not required to be disclosed pursuant to Applicable Law, none of the officers
or directors of the Company is presently a party to any transaction with the Company (other than for services as employees, officers and directors), including any contract, agreement or other arrangement providing for the furnishing of services to
or by, providing for rental of real or personal property to or from, or otherwise requiring payments to or from any officer or director, or to the knowledge of the Company, any corporation, partnership, trust or other entity in which any officer or
director has a substantial interest or is an officer, director, trustee or partner. 
 Section 4.22    Rights of First
Refusal. The Company is not obligated to offer the Common Shares offered hereunder on a right of first refusal basis or otherwise to any third parties including, but not limited to, current or former shareholders of the Company, underwriters,
brokers, agents or other third parties. 
 Section 4.23    Dilution. The Company is aware and acknowledges that issuance of
Common Shares hereunder could cause dilution to existing shareholders and could significantly increase the outstanding number of shares of Common Stock. 

Section 4.24    Acknowledgment Regarding Investor’s Purchase of Shares. The Company acknowledges and agrees that the
Investor is acting solely in the capacity of an arm’s length investor with respect to this Agreement and the transactions contemplated hereunder. The Company further acknowledges that the Investor is not acting as a financial advisor or
fiduciary 

  
 - 17 - 

 
of the Company (or in any similar capacity) with respect to this Agreement and the transactions contemplated hereunder and any advice given by the Investor or any of its representatives or agents
in connection with this Agreement and the transactions contemplated hereunder is merely incidental to the Investor’s purchase of the Shares hereunder. The Company is aware and acknowledges that it shall not be able to request Advances under
this Agreement if the Registration Statement is not effective or if any issuances of Common Shares pursuant to any Advances would violate any rules of the Principal Market. The Company acknowledged and agrees that it is capable of evaluating and
understanding, and understands and accepts, the terms, risks and conditions of the transactions contemplated by this Agreement. 

Section 4.25    Finder’s Fees. Neither the Company nor any of the Subsidiaries has incurred any liability for any
finder’s fees, brokerage commissions or similar payments in connection with the transactions herein contemplated.

Section 4.26    Relationship of the Parties. Neither the Company, nor any of its subsidiaries, affiliates, nor any person
acting on its or their behalf is a client or customer of the Investor or any of its affiliates and neither the Investor nor any of its affiliates has provided, or will provide, any services to the Company or any of its affiliates, its subsidiaries,
or any person acting on its or their behalf. The Investor’s relationship to Company is solely as investor as provided for in the Transaction Documents.

Section 4.27    Operations. The operations of the Company and its Subsidiaries are and have been conducted at all times in
compliance with and neither the Company nor the Subsidiaries, nor any director, officer, or employee of the Company or any Subsidiary nor, to the Company’s knowledge, any agent, affiliate or other person acting on behalf of the Company or any
Subsidiary has, not complied with Applicable Law; and no action, suit or proceeding by or before any governmental authority involving the Company or any of its Subsidiaries with respect to Applicable Laws is pending or, to the knowledge of the
Company, threatened. 
 Section 4.28    Forward-Looking Statements. No forward-looking statement (within the meaning of
Section 27A of the Securities Act and Section 21E of the Exchange Act) contained in the Registration Statement or a Prospectus has been made or reaffirmed without a reasonable basis or has been disclosed other than in good faith. 

Section 4.29    Compliance with Laws. Except as would not have a Material Adverse Effect, the Company and each of its
Subsidiaries are in compliance with Applicable Laws; the Company has not received a notice of non-compliance, nor knows of, nor has reasonable grounds to know of, any facts that any director, officer, or
employee of the Company or any Subsidiary nor, to the Company’s knowledge, any agent, affiliate or other person acting on behalf of the Company or any Subsidiary has, has not complied with Applicable Laws, or could give rise to a notice of non-compliance with Applicable Laws, and is not aware of any pending change or contemplated change to any applicable law or regulation or governmental position; in each case that would materially adversely affect
the business of the Company or the business or legal environment under which the Company operates. 
 Section 4.30    Sanctions
Matters. To the Company’s knowledge, neither the Company nor any of its Subsidiaries or any director, officer or controlled affiliate of the Company or any director or 

  
 - 18 - 

 
officer of any Subsidiary, is a Person that is, or is owned or controlled by a Person that is, (i) the subject of any applicable sanctions administered or enforced by the U.S. Department of
Treasury’s Office of Foreign Asset Control (“OFAC”), the United Nations Security Council, the European Union, Her Majesty’s Treasury or other relevant sanctions authorities with jurisdiction over the Company and its
Subsidiaries, including, without limitation, designation on OFAC’s Specially Designated Nationals and Blocked Persons List or OFAC’s Foreign Sanctions Evaders List (collectively, “Sanctions”), or (ii) located,
organized or resident in a country or territory that is the subject of Sanctions that broadly prohibit dealings with that country or territory (including, without limitation, the Crimea region, the so-called
Donetsk People’s Republic and so-called Luhansk People’s Republic in the Ukraine, Cuba, Iran, North Korea, and Syria). Neither the Company nor any of its Subsidiaries will, directly or knowingly
indirectly, use the proceeds from the sale of Advance Shares or the Promissory Note, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other Person, (a) for the purpose of funding or
facilitating any activities or business of or with any Person or in any country or territory that, at the time of such funding or facilitation, is the subject of Sanctions prohibiting such funding or facilitation or (b) in any other manner that
will knowingly result in a violation of Sanctions or Applicable Laws by any Person (including any Person participating in the transactions contemplated by this Agreement, whether as underwriter, advisor, investor or otherwise). For the past five
years, neither the Company nor any of its Subsidiaries has engaged in, and is now not engaged in, any dealings or transactions with any Person, or in any country or territory, that at the time of the dealing or transaction is or was the subject of
Sanctions prohibiting such dealing or transaction. 
 Section 4.31    General Solicitation. Neither the Company, nor any of
its affiliates, nor any person acting on its or their behalf, has engaged or will engage in any form of general solicitation or general advertising (within the meaning of Regulation D) in connection with the offer or sale of the Common Shares. 

Article V. Indemnification 

The Investor and the Company represent to the other the following with respect to itself: 

Section 5.01    Indemnification by the Company. In consideration of the Investor’s execution and delivery of this
Agreement, and in addition to all of the Company’s other obligations under this Agreement, the Company shall defend, protect, indemnify and hold harmless the Investor and its investment manager, Yorkville Advisors Global, LP, and each of their
respective officers, directors, partners, employees and agents (including, without limitation, those retained in connection with the transactions contemplated by this Agreement) and each person who controls the Investor within the meaning of
Section 15 of the Securities Act or Section 20 of the Exchange Act (collectively, the “Investor Indemnitees”) from and against any and all actions, causes of action, suits, claims, losses, costs, penalties, fees,
liabilities and damages, and reasonable and documented expenses in connection therewith (irrespective of whether any such Investor Indemnitee is a party to the action for which indemnification hereunder is sought), and including reasonable
attorneys’ fees and disbursements (the “Indemnified Liabilities”), incurred by the Investor Indemnitees or any of them as a result of, or arising out of, or relating to (a) any untrue statement or alleged untrue statement
of a material fact contained in the Registration Statement for the registration of the Shares as originally filed or in any amendment thereof, or in any related 

  
 - 19 - 

 
prospectus, or in any amendment thereof or supplement thereto, or arise out of or are based upon the omission or alleged omission to state therein a material fact required to be stated therein or
necessary to make the statements therein not misleading; provided, however, that the Company will not be liable in any such case to the extent that any such loss, claim, damage or liability arises out of or is based upon any such
untrue statement or alleged untrue statement or omission or alleged omission made therein in reliance upon and in conformity with written information furnished to the Company by or on behalf of the Investor specifically for inclusion therein;
(b) any material misrepresentation or breach of any material representation or material warranty made by the Company in this Agreement or any other certificate, instrument or document contemplated hereby or thereby; or (c) any material
breach of any material covenant, material agreement or material obligation of the Company contained in this Agreement or any other certificate, instrument or document contemplated hereby or thereby. To the extent that the foregoing undertaking by
the Company may be unenforceable under Applicable Law, the Company shall make the maximum contribution to the payment and satisfaction of each of the Indemnified Liabilities, which is permissible under Applicable Law. 

Section 5.02    Indemnification by the Investor. In consideration of the Company’s execution and delivery of this
Agreement, and in addition to all of the Investor’s other obligations under this Agreement, the Investor shall defend, protect, indemnify and hold harmless the Company and all of its officers, directors, shareholders, employees and agents
(including, without limitation, those retained in connection with the transactions contemplated by this Agreement) and each person who controls the Investor within the meaning of Section 15 of the Securities Act or Section 20 of the
Exchange Act (collectively, the “Company Indemnitees”) from and against any and all Indemnified Liabilities incurred by the Company Indemnitees or any of them as a result of, or arising out of, or relating to (a) any untrue
statement or alleged untrue statement of a material fact contained in the Registration Statement for the registration of the Shares as originally filed or in any amendment thereof, or in any related prospectus, or in any amendment thereof or
supplement thereto, or arise out of or are based upon the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading; provided, however, that
the Investor will only be liable for written information relating to the Investor furnished to the Company by or on behalf of the Investor specifically for inclusion in the documents referred to in the foregoing indemnity, and will not be liable in
any such case to the extent that any such loss, claim, damage or liability arises out of or is based upon any such untrue statement or alleged untrue statement or omission or alleged omission made therein in reliance upon and in conformity with
written information furnished to the Investor by or on behalf of the Company specifically for inclusion therein; (b) any misrepresentation or breach of any representation or warranty made by the Investor in this Agreement or any instrument or
document contemplated hereby or thereby executed by the Investor; or (c) any breach of any covenant, agreement or obligation of the Investor(s) contained in this Agreement or any other certificate, instrument or document contemplated hereby or
thereby executed by the Investor. To the extent that the foregoing undertaking by the Investor may be unenforceable under Applicable Law, the Investor shall make the maximum contribution to the payment and satisfaction of each of the Indemnified
Liabilities, which is permissible under Applicable Law. 
 Section 5.03    Notice of Claim. Promptly after receipt by an
Investor Indemnitee or Company Indemnitee of notice of the commencement of any action or proceeding (including any 

  
 - 20 - 

 
governmental action or proceeding) involving an Indemnified Liability, such Investor Indemnitee or Company Indemnitee, as applicable, shall, if a claim for an Indemnified Liability in respect
thereof is to be made against any indemnifying party under this Article V, deliver to the indemnifying party a written notice of the commencement thereof; but the failure to so notify the indemnifying party will not relieve it of liability under
this Article V except to the extent the indemnifying party is prejudiced by such failure. The indemnifying party shall have the right to participate in, and, to the extent the indemnifying party so desires, jointly with any other indemnifying party
similarly noticed, to assume control of the defense thereof with counsel mutually reasonably satisfactory to the indemnifying party and the Investor Indemnitee or Company Indemnitee, as the case may be; provided, however, that an Investor Indemnitee
or Company Indemnitee shall have the right to retain its own counsel with the actual and reasonable third party fees and expenses of not more than one counsel for such Investor Indemnitee or Company Indemnitee to be paid by the indemnifying party,
if, in the reasonable opinion of counsel retained by the indemnifying party, the representation by such counsel of the Investor Indemnitee or Company Indemnitee and the indemnifying party would be inappropriate due to actual or potential differing
interests between such Investor Indemnitee or Company Indemnitee and any other party represented by such counsel in such proceeding. The Investor Indemnitee or Company Indemnitee shall cooperate fully with the indemnifying party in connection with
any negotiation or defense of any such action or claim by the indemnifying party and shall furnish to the indemnifying party all information reasonably available to the Investor Indemnitee or Company Indemnitee which relates to such action or claim.
The indemnifying party shall keep the Investor Indemnitee or Company Indemnitee reasonably apprised as to the status of the defense or any settlement negotiations with respect thereto. No indemnifying party shall be liable for any settlement of any
action, claim or proceeding effected without its prior written consent, provided, however, that the indemnifying party shall not unreasonably withhold, delay or condition its consent. No indemnifying party shall, without the prior written consent of
the Investor Indemnitee or Company Indemnitee, consent to entry of any judgment or enter into any settlement or other compromise which does not include as an unconditional term thereof the giving by the claimant or plaintiff to such Investor
Indemnitee or Company Indemnitee of a release from all liability in respect to such claim or litigation. Following indemnification as provided for hereunder, the indemnifying party shall be subrogated to all rights of the Investor Indemnitee or
Company Indemnitee with respect to all third parties, firms or corporations relating to the matter for which indemnification has been made. The indemnification required by this Article V shall be made by periodic payments of the amount thereof
during the course of the investigation or defense, as and when bills are received and payment therefor is due. 

Section 5.04    Remedies. The remedies provided for in this Article V are not exclusive and shall not limit any right or
remedy which may be available to any indemnified person at law or equity. The obligations of the parties to indemnify or make contribution under this Article V shall survive expiration or termination of this Agreement for a period of three years.
Notwithstanding anything to the contrary under this Agreement or Applicable Law, no party shall be entitled to any indemnification pursuant to this Article V (other than claims for any damages resulting from fraud) until the aggregate amount of all
such damages that would otherwise be indemnifiable to such party equals or exceeds $25,000, at which time such party shall be entitled to indemnification for the full amount of all damages. 

  
 - 21 - 

 Section 5.05    Limitation of liability. Notwithstanding the foregoing, no
party shall be entitled to recover from the other party for punitive, indirect, incidental or consequential damages. 
 Article VI.

 Covenants 
 The
Company covenants with the Investor, and the Investor covenants with the Company, as follows, which covenants of one party are for the benefit of the other party, during the Commitment Period: 

Section 6.01    Registration Statement. 
  

	 	(a)	 Filing of a Registration Statement. The Company shall prepare and file with the SEC a Registration
Statement, or multiple Registration Statements for the resale by the Investor of Registrable Securities. The Company in its sole discretion may chose when to file such Registration Statements; provided, however, that the Company shall not
have the ability to request any Advances until the effectiveness of a Registration Statement. 

  

	 	(b)	 Maintaining a Registration Statement. The Company shall use commercially reasonable efforts to maintain
the effectiveness of any Registration Statement at all times during the Commitment Period, provided, however, that if the Company has received notification pursuant to Section 2.04 that the Investor has completed resales pursuant to the
Registration Statement for the full Commitment Amount, then the Company shall be under no further obligation to maintain the effectiveness of the Registration Statement. Notwithstanding anything to the contrary contained in this Agreement, the
Company shall ensure that, when filed, each Registration Statement (including, without limitation, all amendments and supplements thereto) and the prospectus (including, without limitation, all amendments and supplements thereto) used in connection
with such Registration Statement shall not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein, or necessary to make the statements therein (in the case of prospectuses, in the light of the
circumstances in which they were made) not misleading. During the Commitment Period, the Company shall notify the Investor promptly if (i) the Registration Statement shall cease to be effective under the Securities Act, (ii) the Common
Stock shall cease to be authorized for listing on the Principal Market, (iii) the Common Stock shall cease to be registered under Section 12(b) or Section 12(g) of the Exchange Act or (iv) the Company fails to file in a timely
manner all reports and other documents required of it as a reporting company under the Exchange Act. 

  

	 	(c)	 Filing Procedures. Not less than one business day prior to the filing of a Registration Statement and
not less than one business day prior to the filing of any related amendments and supplements to any Registration Statements (except for any amendments or supplements caused by the filing of any annual reports on Form
10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and any similar or successor reports), the Company shall
furnish to the Investor copies of all such documents proposed to be filed, which documents (other than those filed pursuant to Rule 424 promulgated under the Securities Act) will be subject to the reasonable and prompt review of the Investor (in
each of which cases, if such document contains material non-public information as consented 

  
 - 22 - 

	 	
to by the Investor pursuant to Section 6.13, the information provided to Investor will be kept strictly confidential until filed and treated as subject to Section 6.08). The Investor
shall furnish comments on a Registration Statement and any related amendment and supplement to a Registration Statement to the Company within 24 hours of the receipt thereof. If the Investor fails to provide comments to the Company within such 24-hour period, then the Registration Statement, related amendment or related supplement, as applicable, shall be deemed accepted by the Investor in the form originally delivered by the Company to the Investor.

  

	 	(d)	 Delivery of Final Documents. The Company shall furnish to the Investor without charge, (i) at least
one copy of each Registration Statement as declared effective by the SEC and any amendment(s) thereto, including financial statements and schedules, all documents incorporated therein by reference, all exhibits and each preliminary prospectus,
(ii) at the request of the Investor, at least one copy of the final prospectus included in such Registration Statement and all amendments and supplements thereto (or such other number of copies as the Investor may reasonably request) and
(iii) such other documents as the Investor may reasonably request from time to time in order to facilitate the disposition of the Common Shares owned by the Investor pursuant to a Registration Statement. Filing of the forgoing with the SEC via
its EDGAR system shall satisfy the requirements of this section. 

  

	 	(e)	 Amendments and Other Filings. The Company shall (i) prepare and file with the SEC such amendments
(including post-effective amendments) and supplements to a Registration Statement and the related prospectus used in connection with such Registration Statement, which prospectus is to be filed pursuant to Rule 424 promulgated under the Securities
Act, as may be necessary to keep such Registration Statement effective at all times during the Commitment Period, and prepare; (ii) cause the related prospectus to be amended or supplemented by any required prospectus supplement (subject to the
terms of this Agreement), and as so supplemented or amended to be filed pursuant to Rule 424 promulgated under the Securities Act; and (iii) provide the Investor copies of all correspondence from and to the SEC relating to a Registration
Statement (provided that the Company may excise any information contained therein which would constitute material non-public information. 

 

	 	(f)	 Blue-Sky. The Company shall use its commercially reasonable
efforts to, if required by Applicable Law, (i) register and qualify the Common Shares covered by a Registration Statement under such other securities or “blue sky” laws of such jurisdictions in the United States as the Investor
reasonably requests, (ii) prepare and file in those jurisdictions, such amendments (including post-effective amendments) and supplements to such registrations and qualifications as may be necessary to maintain the effectiveness thereof during
the Commitment Period, (iii) take such other actions as may be necessary to maintain such registrations and qualifications in effect at all times during the Commitment Period, and (iv) take all other actions reasonably necessary or
advisable to qualify the Common Shares for sale in such jurisdictions; provided, however, that the Company shall not be required in connection therewith or as a condition thereto to (w) make any change to its Articles of Incorporation or
Bylaws, (x) qualify to do business in any jurisdiction where it would not 

  
 - 23 - 

	 	
otherwise be required to qualify but for this Section 6.01(f), (y) subject itself to general taxation in any such jurisdiction, or (z) file a general consent to service of process in
any such jurisdiction. The Company shall promptly notify the Investor of the receipt by the Company of any notification with respect to the suspension of the registration or qualification of any of the Common Shares for sale under the securities or
“blue sky” laws of any jurisdiction in the United States or its receipt of actual notice of the initiation or threat of any proceeding for such purpose. 

Section 6.02    Suspension of Registration Statement. 

 

	 	(a)	 Establishment of a Black Out Period. During the Commitment Period, the Company from time to time may
suspend the use of the Registration Statement by written notice to the Investor in the event that the Company determines in its sole discretion in good faith that such suspension is necessary to (A) delay the disclosure of material nonpublic
information concerning the Company, the disclosure of which at the time is not, in the good faith opinion of the Company, in the best interests of the Company or (B) amend or supplement the Registration Statement or prospectus so that such
Registration Statement or prospectus shall not include an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they
were made, not misleading (a “Black Out Period”). 

  

	 	(b)	 No Sales by Investor During the Black Out Period. During such Black Out Period, the Investor agrees not
to sell any Common Shares of the Company pursuant to such Registration Statement, but may sell shares pursuant to an exemption from registration, if available, subject to the Investor’s compliance with Applicable Laws. 

 

	 	(c)	 Limitations on the Black Out Period. The Company shall not impose any Black Out Period that is longer
than 45 days or in a manner that is more restrictive (including, without limitation, as to duration) than the comparable restrictions that the Company may impose on transfers of the Company’s equity securities by its directors and senior
executive officers. In addition, the Company shall not deliver any Advance Notice during any Black Out Period. If the public announcement of such material, nonpublic information is made during a Black Out Period, the Black Out Period shall terminate
immediately after such announcement, and the Company shall immediately notify the Investor of the termination of the Black Out Period. 

Section 6.03    Listing of Common Shares. As of each Advance Date, the Shares to be sold by the Company from time to time
hereunder will have been registered under Section 12(b) of the Exchange Act and approved for listing on the Principal Market, subject to official notice of issuance. 

Section 6.04    Opinion of Counsel. Prior to the date of the delivery by the Company of the first Advance Notice, the Investor
shall have received an opinion letter from counsel to the Company in form and substance reasonably satisfactory to the Investor. 

Section 6.05    Exchange Act Registration. The Company will file in a timely manner all reports and other documents required
of it as a reporting company under the Exchange Act and will not take any action or file any document (whether or not permitted by Exchange Act or the rules thereunder) to terminate or suspend its reporting and filing obligations under the Exchange
Act. 

  
 - 24 - 

 Section 6.06    Transfer Agent Instructions. For any time while there is a
Registration Statement in effect for this transaction, the Company shall (if required by the transfer agent for the Common Stock) cause legal counsel for the Company to deliver to the transfer agent for the Common Shares (with a copy to the
Investor) instructions to issue Common Shares to the Investor free of restrictive legends upon each Advance if the delivery of such instructions are consistent with Applicable Law. 

Section 6.07    Corporate Existence. The Company will use commercially reasonable efforts to preserve and continue the
corporate existence of the Company during the Commitment Period. 
 Section 6.08    Notice of Certain Events Affecting
Registration; Suspension of Right to Make an Advance. The Company will promptly notify the Investor, and confirm in writing, upon its becoming aware of the occurrence of any of the following events in respect of a Registration Statement or
related prospectus relating to an offering of Common Shares (in each of which cases the information provided to Investor will be kept strictly confidential): (i) except for requests made in connection with SEC investigations disclosed in the SEC
Documents, receipt of any request for additional information by the SEC or any other Federal or state governmental authority during the period of effectiveness of the Registration Statement or any request for amendments or supplements to the
Registration Statement or related prospectus; (ii) the issuance by the SEC or any other Federal governmental authority of any stop order suspending the effectiveness of the Registration Statement or the initiation of any proceedings for that
purpose; (iii) receipt of any notification with respect to the suspension of the qualification or exemption from qualification of any of the Common Shares for sale in any jurisdiction or the initiation or written threat of any proceeding for
such purpose; (iv) the happening of any event that makes any statement made in the Registration Statement or related prospectus or any document incorporated or deemed to be incorporated therein by reference untrue in any material respect or
that requires the making of any changes in the Registration Statement, related prospectus or documents so that, in the case of the Registration Statement, it will not contain any untrue statement of a material fact or omit to state any material fact
required to be stated therein or necessary to make the statements therein not misleading, and that in the case of the related prospectus, it will not contain any untrue statement of a material fact or omit to state any material fact required to be
stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading, or of the necessity to amend the Registration Statement or supplement a related prospectus to comply with the
Securities Act or any other law; and (v) the Company’s reasonable determination that a post-effective amendment to the Registration Statement would be appropriate; and the Company will promptly make available to the Investor any such
supplement or amendment to the related prospectus. The Company shall not deliver to the Investor any Advance Notice, and the Company shall not sell any Shares pursuant to any pending Advance Notice (other than as required pursuant to
Section 2.02(d)), during the continuation of any of the foregoing events (each of the events described in the immediately preceding clauses (i) through (v), inclusive, a “Material Outside Event”). 

Section 6.09    Consolidation. If an Advance Notice has been delivered to the Investor, then the Company shall not effect any
consolidation of the Company with or into, or a transfer of all or substantially all the assets of the Company to another entity before the transaction contemplated in such Advance Notice has been closed in accordance with Section 2.02 hereof,
and all Shares in connection with such Advance have been received by the Investor. 

  
 - 25 - 

 Section 6.10    Issuance of the Company’s Common Shares. The issuance
and sale of the Common Shares hereunder shall be made in accordance with the provisions and requirements of Section 4(a)(2) of the Securities Act and any applicable state securities law. 

Section 6.11    Market Activities. The Company will not, directly or indirectly, take any action designed to cause or result
in, or that constitutes or might reasonably be expected to constitute, the stabilization or manipulation of the price of any security of the Company under Regulation M of the Exchange Act. 

Section 6.12    Expenses. The Company, whether or not the transactions contemplated hereunder are consummated or this
Agreement is terminated, will pay all expenses incident to the performance of its obligations hereunder, including but not limited to (i) the preparation, printing and filing of the Registration Statement and each amendment and supplement
thereto, of each prospectus and of each amendment and supplement thereto; (ii) the preparation, issuance and delivery of any Shares issued pursuant to this Agreement, (iii) all fees and disbursements of the Company’s counsel,
accountants and other advisors (but not, for the avoidance doubt, the fees and disbursements of Investor’s counsel, accountants and other advisors), (iv) the qualification of the Shares under securities laws in accordance with the provisions of
this Agreement, including filing fees in connection therewith, (v) the printing and delivery of copies of any prospectus and any amendments or supplements thereto, (vi) the fees and expenses incurred in connection with the listing or
qualification of the Shares for trading on the Principal Market, or (vii) filing fees of the SEC and the Principal Market. 

Section 6.13    Current Report. The Company shall not, and the Company shall cause each of its Subsidiaries and each of its
and their respective officers, directors, employees and agents not to, provide the Investor with any material, non-public information regarding the Company or any of its Subsidiaries without the express prior
written consent of the Investor (which may be granted or withheld in the Investor’s sole discretion and if granted must include an agreement to keep such information confidential until publicly disclosed or 45 days have passed); it being
understood that the mere notification of Investor required pursuant to Section 6.08(iv) hereof shall not in and of itself be deemed to be material non-public information. Notwithstanding anything
contained in this Agreement to the contrary, the Company expressly agrees that it shall publicly disclose, no later than four 45 days following the date hereof, but in any event prior to delivering the first Advance Notice hereunder, any information
communicated to the Investor by or, to the knowledge of the Company, on behalf of the Company in connection with the transactions contemplated herein, which, following the date hereof would, if not so disclosed, constitute material, non-public information regarding the Company or its Subsidiaries. 
 Section 6.14    Advance
Notice Limitation. The Company shall not deliver an Advance Notice if a shareholder meeting or corporate action date, or the record date for any shareholder meeting or any corporate action, would fall during the period beginning two Trading Days
prior to the date of delivery of such Advance Notice and ending two Trading Days following the Closing of such Advance. 

  
 - 26 - 

 Section 6.15    Use of Proceeds. The Company will contribute the proceeds
from the sale of the Common Shares hereunder to its subsidiary, BioTE Holdings LLC, which will use the proceeds for working capital and other general corporate purposes or, if different, in a manner consistent with the application thereof described
in the Registration Statement. 
 Section 6.16    Compliance with Laws. The Company shall comply in all material respects
with all Applicable Laws. 
 Section 6.17    Market Activities. Neither the Company, nor any Subsidiary, nor any of their
respective officers, directors or controlling persons will, directly or indirectly, (i) take any action designed to cause or result in, or that constitutes or might reasonably be expected to constitute or result, in the stabilization or
manipulation of the price of any security of the Company to facilitate the sale or resale of Common Shares or (ii) sell, bid for, or purchase Common Shares in violation of Regulation M, or pay anyone any compensation for soliciting purchases of
the Shares. 
 Section 6.18    Trading Information. Upon the Company’s request, the Investor agrees to provide the
Company with trading reports setting forth the number and average sales prices of shares of Common Stock sold by the Investor during the prior trading week. 

Section 6.19    Selling Restrictions. (i) Except as expressly set forth below, the Investor covenants that from and after
the date hereof through and including the first Trading Day following the expiration or termination of this Agreement as provided in Section 11.01 (the “Restricted Period”), none of the Investor, any of its officers or any
entity managed or controlled by the Investor (collectively, the “Restricted Persons” and each of the foregoing is referred to herein as a “Restricted Person”) shall, directly or indirectly, engage in any “short
sale” (as such term is defined in Rule 200 of Regulation SHO of the Exchange Act) of the Common Stock, either for its own principal account or for the principal account of any other Restricted Person. Notwithstanding the foregoing, it is
expressly understood and agreed that nothing contained herein shall (without implication that the contrary would otherwise be true) prohibit any Restricted Person during the Restricted Period from: (1) selling “long” (as defined under
Rule 200 promulgated under Regulation SHO) the Shares; or (2) selling a number of shares of Common Stock equal to the number of Advance Shares that such Restricted Person is unconditionally obligated to purchase under a pending Advance Notice
but has not yet received from the Company or the transfer agent pursuant to this Agreement. 
 Article VII. 

Conditions for Delivery of Advance Notice 

Section 7.01    Conditions Precedent to the Right of the Company to Deliver an Advance Notice. The right of the Company to
deliver an Advance Notice and the obligations of the Investor hereunder with respect to an Advance are subject to the satisfaction or waiver, on each Advance Notice Date (a “Condition Satisfaction Date”), of each of the following
conditions: 
  

	 	(a)	 Accuracy of the Company’s Representations and Warranties. The representations and
warranties of the Company in this Agreement shall be true and correct in all material respects. 

  
 - 27 - 

	 	(b)	 Registration of the Common Shares with the SEC. There is an effective Registration Statement pursuant to
which the Investor is permitted to utilize the prospectus thereunder to resell all of the Common Shares issuable pursuant to such Advance Notice. The Company shall have filed with the SEC in a timely manner all reports, notices and other documents
required under the Exchange Act and applicable SEC regulations during the twelve-month period immediately preceding the applicable Condition Satisfaction Date. 

 

	 	(c)	 Authority. The Company shall have obtained all permits and qualifications required by any applicable
state for the offer and sale of all the Common Shares issuable pursuant to such Advance Notice or shall have the availability of exemptions therefrom. The sale and issuance of such Common Shares shall be legally permitted by all laws and regulations
to which the Company is subject. 

  

	 	(d)	 No Material Outside Event. No Material Outside Event shall have occurred and be continuing.

  

	 	(e)	 Performance by the Company. The Company shall have performed, satisfied and complied in all material
respects with all covenants, agreements and conditions required by this Agreement to be performed, satisfied or complied with by the Company at or prior the applicable Condition Satisfaction Date. 

 

	 	(f)	 No Injunction. No statute, rule, regulation, executive order, decree, ruling or injunction shall have
been enacted, entered, promulgated or endorsed by any court or governmental authority of competent jurisdiction that prohibits or directly, materially and adversely affects any of the transactions contemplated by this Agreement.

  

	 	(g)	 No Suspension of Trading in or Delisting of Common Shares. The Common Stock is quoted for trading on the
Principal Market and all of the Shares issuable pursuant to such Advance Notice will be listed or quoted for trading on the Principal Market. The issuance of Common Shares with respect to the applicable Advance Notice will not violate the
shareholder approval requirements of the Principal Market. The Company shall not have received any written notice that is then still pending threatening the continued quotation of the Common Stock on the Principal Market. 

 

	 	(h)	 Authorized. There shall be a sufficient number of authorized but unissued and otherwise unreserved
Common Shares for the issuance of all of the Shares issuable pursuant to such Advance Notice. 

  

	 	(i)	 Executed Advance Notice. The representations contained in the applicable Advance Notice shall be true
and correct in all material respects as of the applicable Condition Satisfaction Date. 

  

	 	(j)	 Consecutive Advance Notices. Except with respect to the first Advance Notice, the Company shall have
delivered all Shares relating to all prior Advances. 

  
 - 28 - 

 Article VIII. 

Non-Disclosure of Non-Public Information 

The Company covenants and agrees that, other than as expressly required by Section 6.08 hereof, or, with the Investor’s consent pursuant to
Section 6.01(c) and Section 6.13, it shall refrain from disclosing, and shall cause its officers, directors, employees and agents to refrain from disclosing, any material non-public information (as
determined under the Securities Act, the Exchange Act, or the rules and regulations of the SEC) to the Investor without also disseminating such information to the public, unless prior to disclosure of such information the Company identifies such
information as being material non-public information and provides the Investor with the opportunity to accept or refuse to accept such material non-public information
for review. Unless specifically agreed to in writing, in no event shall the Investor have a duty of confidentiality, or be deemed to have agreed to maintain information in confidence, with respect to the delivery of any Advance Notices. 

Article IX. 
 Non-Exclusive Agreement 
 Notwithstanding anything contained herein, this Agreement and the rights
awarded to the Investor hereunder are non-exclusive, and the Company may, at any time throughout the term of this Agreement and thereafter, issue and allot, or undertake to issue and allot, any shares and/or
securities and/or convertible notes, bonds, debentures, options to acquire shares or other securities and/or other facilities which may be converted into or replaced by Common Shares or other securities of the Company, and to extend, renew and/or
recycle any bonds and/or debentures, and/or grant any rights with respect to its existing and/or future share capital. 
 Article X.

 Choice of Law/Jurisdiction 

This Agreement shall be governed by and interpreted in accordance with the laws of the State of New York without regard to the principles of
conflict of laws. The parties further agree that any action between them shall be heard in New York County, New York, and expressly consent to the jurisdiction and venue of the Supreme Court of New York, sitting in New York County, New York and the
United States District Court of the Southern District of New York, sitting in New York, New York, for the adjudication of any civil action asserted pursuant to this Agreement. 

Article XI. Assignment; Termination 

Section 11.01    Assignment. Neither this Agreement nor any rights or obligations of the parties hereto may be assigned to any
other Person. 
 Section 11.02    Termination. 
  

	 	(a)	 Unless earlier terminated as provided hereunder, this Agreement shall terminate automatically on the earliest
of (i) the first day of the month next following the 36-month anniversary of the date hereof or (ii) the date on which the Investor shall have made payment of Advances pursuant to this Agreement for
Common Shares equal to the Commitment Amount. 

  
 - 29 - 

	 	(b)	 The Company may terminate this Agreement effective upon five Trading Days’ prior written notice to the
Investor; provided that (i) there are no outstanding Advance Notices, the Common Shares under which have yet to be issued, and (ii) the Company has paid all amounts owed to the Investor pursuant to this Agreement. This Agreement may be
terminated at any time by the mutual written consent of the parties, effective as of the date of such mutual written consent unless otherwise provided in such written consent. 

 

	 	(c)	 Nothing in this Section 11.02 shall be deemed to release the Company or the Investor from any liability
for any breach under this Agreement, or to impair the rights of the Company and the Investor to compel specific performance by the other party of its obligations under this Agreement. The indemnification provisions contained in Article V shall
survive termination hereunder. 

 Article XII. Notices 

Other than with respect to Advance Notices, which must be in writing and will be deemed delivered on the day set forth in
Section 2.01(b), any notices, consents, waivers, or other communications required or permitted to be given under the terms of this Agreement must be in writing and will be deemed to have been delivered (i) upon receipt, when delivered
personally; (ii) upon receipt, when sent by facsimile or e-mail if sent on a Trading Day, or, if not sent on a Trading Day, on the immediately following Trading Day; (iii) 5 days after being sent by U.S.
certified mail, return receipt requested, (iv) 1 day after deposit with a nationally recognized overnight delivery service, in each case properly addressed to the party to receive the same. The addresses and facsimile numbers for such communications
(except for Advance Notices which shall be delivered in accordance with Exhibit A hereof) shall be: 
  

			
	If to the Company, to:	  	biote Corp.
		  	1875 W. Walnut Hill Ln.
		  	#100
		  	Irving, TX 75038
		  	Attention: General Counsel
		  	Telephone: [***]
		
	With a copy to (which shall not constitute notice or delivery of process) to:	  	
		  	Cooley LLP
		  	Attention: Ryan Sansom, Peter Byrne
		  	Telephone: (617) 937-2300
		  	Email: rsansom@cooley.com, pbyrne@cooley.com

  
 - 30 - 

			
	If to the Investor(s):	  	YA II PN, Ltd.
		  	1012 Springfield Avenue
		  	Mountainside, NJ 07092
		  	Attention:       Mark Angelo
		  	        Portfolio Manager

		  	Telephone:     [***]
		  	Email: [***]
		
	With a Copy (which shall not constitute notice or delivery of process) to:	  	 David Fine, Esq.
 1012 Springfield Avenue

Mountainside, NJ 07092

		  	Telephone:       [***]
		  	Email:              [***]

 or at such other address and/or e-mail and/or to the attention of such other person as
the recipient party has specified by written notice given to each other party three Business Days prior to the effectiveness of such change. Written confirmation of receipt (i) given by the recipient of such notice, consent, waiver or other
communication, (ii) electronically generated by the sender’s email service provider containing the time, date, recipient email address or (iii) provided by a nationally recognized overnight delivery service shall be rebuttable
evidence of personal service, receipt by facsimile or receipt from a nationally recognized overnight delivery service in accordance with clause (i), (ii) or (iii) above, respectively. 

Article XIII. Miscellaneous 

Section 13.01    Counterparts. This Agreement may be executed in identical counterparts, both which shall be considered one
and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party. Facsimile or other electronically scanned and delivered signatures (including any electronic signature covered by
the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act, the Electronic Signatures and Records Act or other applicable law, e.g., www.docusign.com), including by e-mail attachment, shall
be deemed to have been duly and validly delivered and be valid and effective for all purposes of this Agreement. 

Section 13.02    Entire Agreement; Amendments. This Agreement supersedes all other prior oral or written agreements between
the Investor, the Company, their respective affiliates and persons acting on their behalf with respect to the matters discussed herein, and this Agreement contains the entire understanding of the parties with respect to the matters covered herein
and, except as specifically set forth herein, neither the Company nor the Investor makes any representation, warranty, covenant or undertaking with respect to such matters. No provision of this Agreement may be waived or amended other than by an
instrument in writing signed by the parties to this Agreement. 

  
 - 31 - 

 Section 13.03    Reporting Entity for the Common Shares. The reporting
entity relied upon for the determination of the trading price or trading volume of the Common Stock on any given Trading Day for the purposes of this Agreement shall be Bloomberg, L.P. or any successor thereto. The written mutual consent of the
Investor and the Company shall be required to employ any other reporting entity. 
 Section 13.04    Commitment and Structuring
Fee. Each of the parties shall pay its own fees and expenses (including the fees of any attorneys, accountants, appraisers or others engaged by such party) in connection with this Agreement and the transactions contemplated hereby, except
that the Company has paid YA Global II SPV, LLC, a subsidiary of the Investor, a structuring fee in the amount of $15,000 (which the Investor acknowledges has been received) and, on the date hereof, the Company will issue to the Investor an
aggregate of 25,000 shares of Common Stock (the “Commitment Shares”) as a commitment fee. 

Section 13.05    Brokerage. Each of the parties hereto represents that it has had no dealings in connection with this
transaction with any finder or broker who will demand payment of any fee or commission from the other party. The Company on the one hand, and the Investor, on the other hand, agree to indemnify the other against and hold the other harmless from any
and all liabilities to any person claiming brokerage commissions or finder’s fees on account of services purported to have been rendered on behalf of the indemnifying party in connection with this Agreement or the transactions contemplated
hereby. 
 [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 

  
 - 32 - 

 IN WITNESS WHEREOF, the parties hereto have caused this Standby Equity Purchase
Agreement to be executed by the undersigned, thereunto duly authorized, as of the date first set forth above. 
  

					
	COMPANY:
	BIOTE CORP.
		
	By:	 	 /s/ Mary Elizabeth Conlon

	Name: Mary Elizabeth Conlon
	Title:	 	Vice President, Business Development, General Counsel and Secretary
	
	INVESTOR:
	YA II PN, LTD.
		
	By:	 	Yorkville Advisors Global, LP
	Its:	 	Investment Manager
			
		 	By:	 	Yorkville Advisors Global II, LLC
		 	Its:	 	General Partner
			
		 	By:	 	 /s/ Matt Beckman

		 	Name:	 	Matt Beckman
		 	Title:	 	Member

  
 - 33 - 

 EXHIBIT A 

FORM OF ADVANCE NOTICE 

 EXHIBIT B 

FORM OF SETTLEMENT DOCUMENT 

 EXHIBIT C 

LITIGATIONExhibit
10.1

 

AMENDMENT
AGREEMENT

 

This
AMENDMENT AGREEMENT (as amended, the “Agreement”), dated as of July 28, 2022, is made by and between Cryptyde,
Inc., a Delaware corporation, with headquarters located at 2009 9th Avenue North, Suite 220, Safety Harbor, Florida 34695 (“TYDE”)
and the investor listed on the signature page attached hereto (the “Holder”). Capitalized terms used herein and not
otherwise defined herein shall have the respective meanings set forth in the Note, SPA, RRA and/or Warrants (each as defined below),
as applicable.

 

A.
Pursuant to that certain Securities Purchase Agreement (as amended, the “SPA”) dated as of January 26, 2022 by and
between TYDE and the Holder, TYDE sold to the Holder a Senior Secured Convertible Note in an aggregate principal amount of $33,333,333
(as amended, the “Note”) and warrants representing the right to acquire shares of TYDE’s common stock, $0.001
par value per share (the “Common Stock”) (as amended, the “Warrants”).

 

B.
TYDE desires to repurchase a portion of the Note and the parties, including the Holders representing the Required Holders (as defined
in each of the SPA, the RRA and the Note), hereto desire among other things: (i) to amend certain provisions of the Note as set forth
herein and (ii) to amend certain provisions of the SPA and the registration rights agreement dated as of January 26, 2022 by and between
TYDE and the Buyers (as defined therein) (the “RRA”) as set forth herein.

 

NOW
THEREFORE, in consideration of the foregoing mutual premises and the covenants and agreements hereinafter set forth, and for other
good and valuable consideration, the receipt, and legal adequacy of which is hereby acknowledged, the parties hereto, intending to be
legally bound, hereby agree as follows:

 

1.
REPURCHASE OF NOTE. Subject to the satisfaction (or waiver) of the conditions set forth in Sections 7 and 8 below, the parties
hereto hereby agree that:

 

(a)
On the Closing Date (as defined below), TYDE shall repurchase (the “Company Repurchase”)
$22,000,000 of the Principal of the Conversion Amount of the Note then outstanding (the “Company Repurchase Amount”).
The Company Repurchase Amount shall be repurchased by TYDE for $22,000,000 (the “Company Repurchase Price”) in cash
by wire transfer of immediately available funds pursuant to Holder’s wire instructions set forth on the Holder’s signature
page attached hereto. The Company shall pay the Company Repurchase Price from the cash deposited in the Control Account. To the extent
the Company Repurchase made pursuant to this Section 1(a) is deemed or determined by a court of competent jurisdiction to be a prepayment
of the Note by TYDE, such repurchase shall be deemed to be a voluntary prepayment. Notwithstanding anything to the contrary in this Section
1(a), but subject to Section 3(d) of the Note, until the Company Repurchase Amount is paid in full, the Company Repurchase Amount (together
with any Interest and Late Charges thereon) may be converted, in whole or in part, by the Holder into Common Stock pursuant to Section
3 of the Note. The parties hereto agree that in the event TYDE fails to repurchase any portion of the Note under this Section 1(a), the
Holder’s damages would be uncertain and difficult to estimate because of the parties’ inability to predict future interest
rates and the uncertainty of the availability of a suitable substitute investment opportunity for the Holder.

 

    	1

    	 

    

 

2. AMENDMENT OF Note.

 

(a)
The Conversion Price of the balance of the Note that remains outstanding immediately following the Initial Company Repurchase shall be
voluntarily and irrevocably adjusted to equal $1.06, subject to further adjustments as provided in the Note (the “Conversion
Price Voluntary Adjustment”).

 

(b)
Section 13(p) of the Note is hereby amended and restated in its entirety as follows (strikethrough indicates deletion; bold underline
indicates addition):

 

“(p)
Control Account. The Company shall at all times maintain on deposit in the Control Account cash in an aggregate amount equal to
not less than the Purchase Price paid by the initial Holder of this Note to the Company
on the Closing Date $1,000,000 plus the applicable Warrant Exercise Cash Percentage of any Warrant Exercise Cash
(each as defined in that certain Amendment Agreement, dated as of July 28, 2022, by and between the Company and Hudson Bay Master Fund
Ltd.); provided, however, that in the event (A) the Spin-Off is consummated on terms acceptable to the Required Holders
on or prior to [•], the Price Condition has been satisfied as of the Cash Release Notice Date (as defined below), (CB)
the Volume Condition has been satisfied as of the Cash Release Notice Date and (DC) no Equity Conditions
Failure has occurred that is then continuing as of the Cash Release Notice Date (the conditions set forth in clause (A), (B) and,
(C) and (D) are collectively referred to herein as the “Release Conditions”), the Company
may give written notice (the “Cash Release Notice” and the date the Holder and all the holders of the Other Notes received
such notice is referred to as the “Cash Release Notice Date”) to the Holder of its intention to release such Purchase Price
from the Control Account certifying that the Release Conditions have been satisfied as of the Cash Release Notice Date and setting forth
the date of such release on a date that is not less than five (5) Business Days following the Cash Release Notice Date. The Cash Release
Notice shall not contain any material, nonpublic information with respect to the Company or BBIG or subject the Holder to any duty of
confidentiality. For the avoidance of doubt, for purposes of this Section 13(p) the Equity Conditions Measurement Period shall have commenced
on the thirtieth (30th) calendar day prior to the delivery of the Cash Release Notice and have ended on the Cash Release Notice Date.”

 

(c)
The definition of “Permitted Indebtedness” set forth in Section 31(ee) of the Note is hereby amended to include a new clause
(m) at the end, as follows:

 

“(m)
technology licenses; provided, however, that (i) such technology licenses do not require the Company or any of its Subsidiaries
to make any cash payment during the first two (2) years following the signing of such technology licenses and the Company shall not be
permitted to make any voluntary cash payment during such period, (ii) such technology licenses in the aggregate do not obligate the Company
or its Subsidiary, as applicable, to incur cash obligations in excess of $10,000,000, (iii) in connection with the entry into such technology
licenses, the Company or its Subsidiary, as applicable, enters into an intercreditor agreement that is acceptable to the Required Holders,
(iv) in connection with the entry into such technology licenses, the Company or its Subsidiary, as applicable, does not issue more than
250,000 shares of Common Stock (as adjusted for any stock dividend, stock split, stock combination, reclassification or similar transaction
with respect to the Common Stock occurring after July 28, 2022) and (v) such securities are issued as “restricted securities”
(as defined in Rule 144) and carry no registration rights that require or permit the filing of any registration statement in connection
therewith during the prohibition period set forth in Section 4(k) of the SPA.”

 

    	2

    	 

    

 

(d)
Clause (n) of the definition of “Permitted Liens” set forth in Section 31(ff) of the Note is hereby amended and restated
in its entirety, as follows (strikethrough indicates deletion; bold underline indicates addition):

 

“(n)
Liens (i) upon or in any equipment acquired or held by the Company or any of its Subsidiaries to secure the purchase price of such equipment
or Indebtedness incurred solely for the purpose of financing the acquisition or lease of such equipment, or (ii) existing on such equipment
at the time of its acquisition, provided that the Lien is confined solely to the property so acquired and improvements thereon, and the
proceeds of such equipment, in either case, with respect to Indebtedness in an aggregate amount not to exceed $500,000
$10,000,000.”

 

3. Amendment of SPA AND RRA.

 

(a)
Section 4(k) of the SPA is hereby amended and restated in its entirety as follows (strikethrough indicates deletion; bold underline indicates
addition):

 

“(k)
Additional Issuance of Securities. So long as any Buyer beneficially owns any Securities, the Company will not, without the prior
written consent of the Required Holders, issue any Notes (other than to the Buyers as contemplated hereby) and the Company shall not
issue any other securities that would cause a breach or default under the Notes or the Warrants. The Company agrees that for the period
commencing on the date hereof and ending on the date immediately following the Applicable Date (provided that such period shall be extended
by the number of calendar days during such period and any extension thereof contemplated by this proviso on which any Registration Statement
is not effective or any prospectus contained therein is not available for use or any Current Public Information Failure exists) (the
“Restricted Period”), neither the Company nor any of its Subsidiaries shall directly or indirectly issue, offer, sell,
grant any option or right to purchase, or otherwise dispose of (or announce any issuance, offer, sale, grant of any option or right to
purchase or other disposition of) any equity security or any equity-linked or related security (including, without limitation, any “equity
security” (as that term is defined under Rule 405 promulgated under the 1933 Act), any Convertible Securities (as defined below),
any debt, any preferred stock or any purchase rights) (any such issuance, offer, sale, grant, disposition or announcement (whether occurring
during the Restricted Period or at any time thereafter) is referred to as a “Subsequent Placement”). Notwithstanding
the foregoing, this Section 4(k) shall

 

    	3

    	 

    

 

not
apply in respect of the issuance of (i) shares of Common Stock or standard options to purchase Common Stock to directors, officers or
employees of the Company in their capacity as such pursuant to an Approved Stock Plan (as defined below), provided that (1) such
securities are issued as “restricted securities” (as defined in Rule 144) and carry no registration rights that require or
permit the filing of any registration statement in connection therewith during the prohibition period set forth herein, (2)
all such issuances (taking into account the shares of Common Stock issuable upon exercise of such options) after the date hereof pursuant
to this clause (i) do not, in the aggregate, exceed more than the limits set forth in the Approved Stock Plans 20%
of the Common Stock issued and outstanding immediately following the Spin-Off (as defined in the Note) and (2) the exercise
price of any such options is not lowered, none of such options are amended to increase the number of shares issuable thereunder and none
of the terms or conditions of any such options are otherwise materially changed in any manner that adversely affects any of the Buyers;
(ii) shares of Common Stock issued upon the conversion or exercise of Convertible Securities (other than standard options to purchase
Common Stock issued pursuant to an Approved Stock Plan that are covered by clause (i) above) issued prior to the date hereof, provided
that the conversion, exercise or other method of issuance (as the case may be) of any such Convertible Security is made solely pursuant
to the conversion, exercise or other method of issuance (as the case may be) provisions of such Convertible Security that were in effect
on the date immediately prior to the date of this Agreement, the conversion, exercise or issuance price of any such Convertible Securities
(other than standard options to purchase Common Stock issued pursuant to an Approved Stock Plan that are covered by clause (i) above)
is not lowered, none of such Convertible Securities (other than standard options to purchase Common Stock issued pursuant to an Approved
Stock Plan that are covered by clause (i) above) are amended to increase the number of shares issuable thereunder and none of the terms
or conditions of any such Convertible Securities (other than standard options to purchase Common Stock issued pursuant to an Approved
Stock Plan that are covered by clause (i) above) are otherwise materially changed in any manner that adversely affects any of the Buyers;
(iii) the Conversion Shares; provided, that the terms of the Notes are not amended, modified or changed on or after the date hereof,
(iv) the Warrant Shares; provided, that the terms of the Warrants are not amended, modified or changed on or after the date hereof,
(v) any Common Stock issued or issuable by the Company on or prior to the Closing in a Permitted Subsequent Placement (as defined in
the Warrants); provided, that the terms of the Permitted Subsequent Placement are not amended, modified or changed on or after the
date hereof, (vi) shares of Common Stock issued pursuant to acquisitions or strategic transactions provided that such securities are
issued as “restricted securities” (as defined in Rule 144) and carry no registration rights that require or permit the filing
of any registration statement in connection therewith during the prohibition period set forth herein, and, provided that any such issuance
shall only be to a Person (or to the equityholders of a Person) which is, itself or through its subsidiaries, an operating company or
an owner of an asset in a business synergistic with the business of the Company and shall provide to the Company additional benefits
in

 

    	4

    	 

    

 

addition
to the investment of funds, but (1) shall not include a transaction in which the Company is issuing securities primarily for the purpose
of raising capital or to an entity whose primary business is investing in securities, and (2) all such issuances after the date hereof
pursuant to this clause (vi) do not, in the aggregate, exceed more than 10% of the Common Stock issued and outstanding immediately
following the Spin-Off (as defined in the Notes) as of the date of the consummation of the first acquisition or strategic
transaction occurring on or after July 28, 2022, and (vii) as set forth in Schedule 4(k), provided that such securities set forth
in Schedule 4(k)(i) are issued as “restricted securities” (as defined in Rule 144) and carry no registration rights that
require or permit the filing of any registration statement in connection therewith during the prohibition period set forth herein (each
of the foregoing in clauses (i) through (vii), collectively the “Excluded Securities”). “Approved Stock Plan”
means any employee benefit plan which has been approved by the board of directors of the Company prior to or subsequent to the date hereof
pursuant to which shares of Common Stock and standard options to purchase Common Stock may be issued to any employee, officer or director
for services provided to the Company in their capacity as such.”

 

(b)
The definition of “Registrable Securities” set forth in Section 1(i) of the RRA is hereby amended and restated in its entirety
as follows (strikethrough indicates deletion; bold underline indicates addition):

 

““Registrable
Securities” means (i) the Conversion Shares, (ii) the Warrant Shares and (iii) any capital stock of the Company issued or issuable
with respect to the Conversion Shares, the Warrant Shares, the Notes or the Warrants, including, without limitation, (1) as a result
of any stock split, stock dividend, recapitalization, exchange, adjustment to the Conversion Price or Exercise Price or
similar event or otherwise and (2) shares of capital stock of the Company into which the shares of Common Stock (as defined in the Notes)
are converted or exchanged and shares of capital stock of a Successor Entity (as defined in the Warrants) into which the shares of Common
Stock are converted or exchanged, in each case, without regard to any limitations on conversion of the Notes or exercise of the Warrants.”

 

(c)
The definition of “Required Registration Amount” set forth in Section 1(l) of the RRA is hereby amended and restated in its
entirety as follows (strikethrough indicates deletion; bold underline indicates addition):

 

““Required
Registration Amount” means the sum of (i) 200% of the maximum number
of Conversion Shares issuable upon conversion of the Notes (assuming for purposes hereof that (x) the Notes are convertible at the then
applicable initial Conversion Price (as defined in the Notes) and (y) any such conversion shall not take into
account any limitations on the conversion of the Notes set forth in the Notes) and (ii) 200% of the maximum number of Warrant Shares
issuable upon exercise of the Warrants (without taking into account any limitations on the exercise of the Warrants set forth therein)
assuming all cash has been released from the Control Account (as defined in the Notes), all subject to adjustment as provided
in Section 2(d) and/or Section 2(f).”

 

    	5

    	 

    

 

4. ADDITIONAL AGREEMENTS.

 

(a)
The parties hereby agree and acknowledge that, as a result of the Conversion Price Voluntary Adjustment, the Exercise Price of the Warrants
shall be adjusted pursuant to Section 2(a) thereof to equal $1.06, subject to further adjustments as provided therein.

 

(b)
On (i) the Closing Date, TYDE shall be permitted to release $25,533,332, from the Control Account to its own account and (ii) the Nasdaq
Approval Date, TYDE shall be permitted to release $3,466,668 plus 50% of any Warrant Exercise Cash deposited into Control Account prior
to the Nasdaq Approval Date from the Control Account to its own account, a portion of which shall be used to pay the applicable Company
Repurchase Price in full pursuant to Section 1(a). Immediately following the cash releases from the Control Account set forth in the
immediately preceding sentence there shall remain cash in the Control Account in an amount equal to not less than $1,000,000. The parties
hereby agree and acknowledge that the cash releases from the Control Account set forth in the first sentence of this Section 4(b) shall
satisfy the cash release condition set forth in the proviso at the end of the first sentence of Section 2(a) of the Warrants to the extent
of the amount of cash so released from the Control Account. As used herein, “Nasdaq Approval Date” means a date on
or prior to August 16, 2022 when TYDE shall secure a listing acceptable to TYDE and the Required Holders on the Principal Market of the
additional shares of Common Stock issuable upon conversion of the Note resulting from the Conversion Price Voluntary Adjustment (subject
to official notice of issuance). TYDE shall pay all fees and expenses in connection with satisfying its obligations to secure the listing
on the Principal Market of the additional shares of Common Stock issuable upon conversion of the Note.

 

(c)
For the avoidance of doubt, TYDE agrees that both (i) the Conversion Price Voluntary Adjustment will cause an adjustment to the number
of Conversion Shares and (ii) the adjustment to the number of shares of Common Stock issuable upon exercise of the Warrants (without
any regard to any limitation or restriction on conversion or exercise set forth therein) pursuant to section 2(c) of the Warrants, which,
together with the amendments to the RRA set forth in Section 3 herein, will require TYDE, in accordance with Section 2(d) of the RRA,
to amend TYDE’s registration statement on Form S-1 with Registration No. 333-264777 (the “Registration Statement”)
(if permissible) or file a new registration statement with the SEC, or both, so as to cover at least the Required Registration Amount
(as defined in the RRA, as amended herein) as of the Trading Day immediately preceding the date of the filing of such amendment or new
registration statement, in each case, as soon as practicable, but in any event not later than fifteen (15) days after the Closing Date.

 

(d)
Upon the exercise of any warrant to purchase shares of Common Stock issued by TYDE on or prior to the date hereof or that TYDE may from
time to time issue following the date hereof, including, but not limited, the Warrants, whereby the holder of such warrants is paying
the applicable exercise price in cash (such cash amount, the “Warrant Exercise Cash”), TYDE shall deposit the Warrant
Exercise Cash Percentage (as defined below) of such Warrant Exercise Cash in to the Control Account. Any holder of such warrant may wire
the Warrant Exercise Cash Percentage of its Warrant Exercise Cash directly to the Control Account with the balance of its exercise price
being paid directly to the Company. As used herein, “Warrant Exercise Cash Percentage” means (i) prior to the Nasdaq
Approval Date, one hundred percent (100%) and (ii) from and after the Nasdaq Approval Date, fifty percent (50%).

 

    	6

    	 

    

 

(e)
Except as otherwise expressly provided herein, each Transaction Document (as defined in the SPA), is, and shall continue to be, in full
force and effect and is hereby ratified and confirmed in all respects.

 

(f)
At any time or times after December 27, 2023, the Holder shall have the right, in its sole and absolute discretion, to require that TYDE
redeem (a “Holder Optional Redemption”) all or any portion of the Holder Optional Redemption Amount (as defined below)
of the Note then outstanding by delivering written notice thereof (a “Holder Optional Redemption Notice” and the date
the Holder delivers such notice to TYDE, a “Holder Optional Redemption Notice Date”) to TYDE which notice shall state
(i) the portion of the Note that is being redeemed by the Holder, (ii) the date on which the Holder Optional Redemption shall occur,
which date shall be the second (2nd) Business Day from the applicable Holder Optional Redemption Notice Date (a “Holder
Optional Redemption Date”) and (iii) the wire instructions for the payment of the applicable Holder Optional Redemption Price
(as defined below) to the Holder. The portion of the Note subject to redemption pursuant to this Section 4(f) shall be redeemed by TYDE
in cash at a price equal to 100% of the Holder Optional Redemption Amount being redeemed, including, without limitation, any accrued
and unpaid Interest and Late Charges, if any, on such Holder Optional Redemption Amount and Interest through the applicable Holder Optional
Redemption Date (a “Holder Optional Redemption Price”). On the applicable Holder Optional Redemption Date, TYDE shall
deliver or shall cause to be delivered to the Holder the Holder Optional Redemption Price in cash by wire transfer of immediately available
funds pursuant to wire instructions provided by the Holder in writing to TYDE. Holder Optional Redemptions made pursuant to this Section
4(f) shall be made in accordance with Section 11 of the Note. To the extent redemptions required by this Section 4(f) are deemed or determined
by a court of competent jurisdiction to be prepayments of the Note by TYDE, such redemptions shall be deemed to be voluntary prepayments.
The parties hereto agree that in the event of TYDE’s redemption of any portion of the Note under this Section 4(f), the Holder’s
damages would be uncertain and difficult to estimate because of the parties’ inability to predict future interest rates and the
uncertainty of the availability of a suitable substitute investment opportunity for the Holder. As used herein, “Holder Optional
Redemption Amount” means the Conversion Amount of this Note outstanding as of any applicable date of determination following
December 27, 2023. TYDE’s failure to deliver the applicable Holder Optional Redemption Price pursuant to the terms of this Section
4(f) shall be deemed an “Event of Default” under the Note.

 

(g)
The parties hereby acknowledge and agree that this Agreement shall be deemed a “Transaction Document” as defined in the SPA
and the other Transaction Documents (as defined in the SPA).

 

(h)
The parties acknowledge and agree that notwithstanding anything to the contrary set forth in the Note, until the Nasdaq Approval Date,
the Holder shall not convert more than $3,533,332 of the Conversion Amount of the Note.

 

5. CLOSING.

 

The
date and time of the closing (the “Closing”) of the transactions contemplated herein (the “Closing Date”)
shall be 9:00 a.m., New York City time, on the date hereof, subject to the notification of satisfaction (or waiver) of the conditions
to Closing set forth in Sections 7 and 8 hereof. The Closing shall occur at the offices of Schulte Roth & Zabel LLP, 919 Third Avenue,
New York, New York 10022 and may be undertaken remotely by electronic exchange of documentation.

 

    	7

    	 

    

 

6. REPRESENTATIONS, AGREEMENTS, WARRANTIES AND COVENANTS.

 

(a)
Holder Representations, Warranties and Covenants. The Holder hereby represents and warrants to TYDE that:

 

(i)
Authorization; Enforcement; Validity. The Holder has the power and authority to execute and deliver this Agreement and perform
its obligations hereunder; and this Agreement and the transactions contemplated hereby and thereby have been duly authorized by the Holder.
This Agreement has been duly and validly authorized, executed and delivered on behalf of the Holder and shall constitute the legal, valid
and binding obligations of the Holder enforceable against the Holder in accordance with its terms, except as such enforceability may
be limited by general principles of equity or to applicable bankruptcy, insolvency, reorganization, moratorium, liquidation and other
similar laws relating to, or affecting generally, the enforcement of applicable creditors’ rights and remedies.

 

(ii)
No Conflicts. The execution, delivery and performance by the Holder of this Agreement and the consummation by the Holder of the
transactions contemplated hereby will not (i) result in a violation of the organizational documents of the Holder or (ii) conflict with,
or constitute a default (or an event which with notice or lapse of time or both would become a default) under, or give to others any
rights of termination, amendment, acceleration or cancellation of, any agreement, indenture or instrument to which the Holder is a party,
or (iii) result in a violation of any law, rule, regulation, order, judgment or decree (including federal and state securities laws)
applicable to the Holder, except in the case of clauses (ii) and (iii) above, for such conflicts, defaults, rights or violations which
would not, individually or in the aggregate, reasonably be expected to have a material adverse effect on the ability of the Holder to
perform its obligations hereunder.

 

(b)
TYDE Representations, Warranties and Covenants. TYDE hereby represents, warrants, agrees and covenants to and with the Holder
that:

 

(i)
Organization and Qualification. TYDE and its subsidiaries are entities duly organized and validly existing and in good standing
under the laws of the jurisdiction in which they are formed, and have the requisite power and authorization to own their properties and
to carry on their business as now being conducted and as presently proposed to be conducted. TYDE and its subsidiaries is duly qualified
as a foreign entity to do business and is in good standing in every jurisdiction in which its ownership of property or the nature of
the business conducted by it makes such qualification necessary, except to the extent that the failure to be so qualified or be in good
standing would not reasonably be expected to have a Material Adverse Effect. As used in this Agreement, “Material Adverse Effect”
means any material adverse effect on the business, properties, assets, liabilities, operations, results of operations, condition (financial
or otherwise) or prospects of TYDE and its subsidiaries, individually or taken as a whole, or on the transactions contemplated hereby
or by the agreements and instruments to be entered into in connection herewith, or on the authority or ability of TYDE to perform any
of its obligations hereunder.

 

    	8

    	 

    

 

(ii)
Authorization; Enforcement; Validity. TYDE has the requisite corporate power and authority to enter into and perform its obligations
under this Agreement. The execution and delivery of this Agreement by TYDE, and the consummation by TYDE of the transactions contemplated
hereby have been duly authorized by TYDE’s Board of Directors and no further filing, consent or authorization is required by TYDE,
its Board of Directors or its stockholders. This Agreement has been duly executed and delivered by TYDE and constitutes the legal, valid
and binding obligations of TYDE enforceable against TYDE in accordance with its terms, except as such enforceability may be limited by
general principles of equity or applicable bankruptcy, insolvency, reorganization, moratorium, liquidation or similar laws relating to,
or affecting generally, the enforcement of applicable creditors’ rights and remedies.

 

(iii)
Reservation of Shares. As of the date hereof, TYDE has duly authorized and reserved for issuance all shares of Common Stock issued
and issuable upon conversion of the Note and exercise of the Warrants after giving effect to the Conversion Price Voluntary Adjustment
(without regard to any limitation or restriction on conversion set forth therein).

 

(iv)
No Conflicts. The execution, delivery and performance of this Agreement by TYDE and the consummation by TYDE of the transactions
contemplated hereby will not (i) result in a violation of TYDE’s Articles of Incorporation or Bylaws or other organizational documents
of TYDE or any of its subsidiaries, any capital stock of TYDE or any of its subsidiaries or the articles of association or bylaws of
TYDE or any of its subsidiaries or (ii) conflict with, or constitute a default (or an event which with notice or lapse of time or both
would become a default) in any respect under, or give to others any rights of termination, amendment, acceleration or cancellation of,
any agreement, indenture or instrument to which TYDE or any of its subsidiaries is a party, or (iii) result in a violation of any law,
rule, regulation, order, judgment or decree (including foreign, federal and state securities laws and regulations and the rules and regulations
of the Principal Market and including all applicable foreign, federal laws, rules and regulations) applicable to TYDE or any of its subsidiaries
or by which any property or asset of TYDE or any of its subsidiaries is bound or affected.

 

(v)
Consents. TYDE is not required to obtain any consent from, authorization or order of, or make any filing or registration with
any court, governmental agency or any regulatory or self-regulatory agency or any other Person in order for it to execute, deliver or
perform any of its obligations under or contemplated by this Agreement in accordance with the terms hereof. All consents, authorizations,
orders, filings and registrations which TYDE is required to obtain pursuant to the preceding sentence have been obtained or effected
on or prior to the Closing Date, and TYDE is not aware of any facts or circumstances which might prevent TYDE from obtaining or effecting
any of the registration, application or filings contemplated by this Agreement. TYDE is not in violation of the requirements of the Principal
Market and has no knowledge of any facts or circumstances which could reasonably lead to delisting or suspension of the Common Stock
in the foreseeable future.

 

    	9

    	 

    

 

(vi)
Absence of Litigation. There is no action, suit, proceeding, inquiry or investigation before or by the Principal Market, any court,
public board, government agency, self-regulatory organization or body pending or, to the knowledge of TYDE, threatened against or affecting
TYDE or any of its subsidiaries, the Common Stock or any of TYDE’s subsidiaries or any of TYDE’s or its subsidiaries’
officers or directors, whether of a civil or criminal nature or otherwise, in their capacities as such.

 

(vii)
Public Disclosure. On or before 9:30 a.m., New York time, on the date hereof, TYDE shall file a Current Report on Form 8-K describing
all the material terms of the transactions contemplated by this Agreement, in each case, in the form required by the 1934 Act and attaching
this Agreement (and all schedules to this Agreement) (including all attachments, the “8-K Filing”). From and after
the filing of the 8-K Filing, TYDE and its Subsidiaries shall have disclosed all material, non-public information (if any) provided to
the Holder by TYDE or any of its Subsidiaries or any of their respective officers, directors, affiliates, employees or agents in connection
with the transactions contemplated by this Agreement. In addition, effective upon the filing of the 8-K Filing, each of TYDE and its
Subsidiaries acknowledges and agrees that any and all confidentiality or similar obligations under any agreement, whether written or
oral, between TYDE, any of its Subsidiaries or any of their respective officers, directors, affiliates, employees or agents, on the one
hand, and the Holder or any of its affiliates, on the other hand, shall terminate and be of no further force or effect. TYDE shall not,
and shall cause each of their respective subsidiaries and its and each of their respective officers, directors, Affiliates, employees
and agents, not to, provide the Holder with any material, nonpublic information regarding TYDE or any of its subsidiaries from and after
the date hereof without the express prior written consent of the Holder. To the extent that TYDE, any of its subsidiaries or any of their
respective officers, directors, Affiliates employees or agents delivers any material, non-public information to the Holder without the
Holder’s express prior written consent, TYDE hereby covenants and agrees that the Holder’s shall not have any duty of confidentiality
to TYDE, any of its subsidiaries or any of their respective officers, directors, Affiliates, employees or agents with respect to, or
a duty to TYDE, any of its subsidiaries or any of their respective officers, directors, Affiliates, employees or agents not to trade
on the basis of, such material, non-public information. TYDE understands and confirms that the Holder will rely on the foregoing representations
in effecting transactions in securities of TYDE.

 

(viii)
No MNPI. TYDE hereby agrees and acknowledges that neither it nor any of its Subsidiaries or any of their respective officers,
directors, affiliates, employees or agents has provided to the Holder any material, nonpublic information of Vinco Ventures Inc. or any
of its subsidiaries.

 

(ix)
Reporting Status. Until the date on which the Holder has sold all the shares of Common Stock issued and issuable upon exercise
of the Warrants and conversion of the Note (without regard to any limitation or restriction on exercise or conversion set forth therein),
TYDE shall timely file all reports required to be filed with the SEC pursuant to the 1934 Act, and TYDE shall not terminate its status
as an issuer required to file reports under the 1934 Act even if the 1934 Act or the rules and regulations thereunder would no longer
require or otherwise permit such termination.

 

    	10

    	 

    

 

(x) Investment
Company Status. TYDE is not, and upon consummation of the transactions contemplated hereunder will not be, an “investment company,”
an affiliate of an “investment company,” a company controlled by an “investment company” or an “affiliated
person” of, or “promoter” or “principal underwriter” for, an “investment company” as such terms
are defined in the Investment Company Act of 1940, as amended.

 

(xi) Acknowledgement
Regarding Holder’s Trading Activity. It is understood and acknowledged by TYDE that (i) following the public disclosure of
the transactions contemplated by this Agreement, in accordance with the terms thereof, the Holder has not been asked by TYDE or any of
its subsidiaries to agree, nor has the Holder agreed with TYDE or any of its subsidiaries, to desist from effecting any transactions
in or with respect to (including, without limitation, purchasing or selling, long and/or short) any securities of TYDE, or “derivative”
securities based on securities issued by TYDE or to hold any securities for any specified term; (ii) the Holder, and counterparties in
“derivative” transactions to which the Holder is a party, directly or indirectly, presently may have a “short”
position in the Common Stock which was established prior to such Holder’s knowledge of the transactions contemplated by this Agreement;
(iii) the Holder shall not be deemed to have any affiliation with or control over any arm’s-length counterparty in any “derivative”
transaction; and (iv) the Holder may rely on TYDE obligation to timely deliver shares of Common Stock upon exercise of the Warrants and
conversion of the Note and when required pursuant to the terms thereof for purposes of effecting trading in the Common Stock. TYDE further
understands and acknowledges that following the public disclosure of the transactions contemplated by this Agreement pursuant to the
8-K Filing the Holder may engage in hedging and/or trading activities (including, without limitation, the location and/or reservation
of borrowable shares of Common Stock) at various times during the period that the Warrants, the Note or the shares of Common Stock issuable
upon exercise or conversion thereof are outstanding, including, without limitation, during the periods that the value and/or number of
the such shares of Common Stock deliverable thereunder are being determined and such hedging and/or trading activities (including, without
limitation, the location and/or reservation of borrowable shares of Common Stock), if any, can reduce the value of the existing stockholders’
equity interest in TYDE both at and after the time the hedging and/or trading activities are being conducted. TYDE acknowledges that
such aforementioned hedging and/or trading activities do not constitute a breach of this Agreement or any of the documents executed in
connection herewith or therewith.

 

(xii) Equity
Capitalization. 

 

(1) Definitions:

 

(A) “Common
Stock” means (x) TYDE’s shares of common stock, $0.001 par value per share, and (y) any capital stock into which such
common stock shall have been changed or any share capital resulting from a reclassification of such common stock.

 

(B) “Convertible
Securities” means any capital stock or other security of TYDE or any of its Subsidiaries that is at any time and under any
circumstances directly or indirectly convertible into, exercisable or exchangeable for, or which otherwise entitles the holder thereof
to acquire, any capital stock or other security of TYDE (including, without limitation, Common Stock) or any of its Subsidiaries.

 

    	11

    	 

    

 

(C) “Preferred
Stock” means (x) TYDE’s blank check preferred stock, $0.001 par value per share, the terms of which may be designated
by the board of directors of TYDE in a certificate of designations and (y) any capital stock into which such preferred stock shall have
been changed or any share capital resulting from a reclassification of such preferred stock (other than a conversion of such preferred
stock into Common Stock in accordance with the terms of such certificate of designations).

 

(2) Authorized
and Outstanding Capital Stock. As of the date hereof, the authorized capital stock of TYDE consists of 260,000,000 shares of capital
stock, consisting of 250,000,000 shares of Common Stock and 10,000,000 shares of preferred stock. As of the date hereof, there are [●]
shares of Common Stock issued and outstanding no shares of TYDE’s preferred stock issued and outstanding.

 

(3) Valid
Issuance; Available Shares; Affiliates. All of such outstanding shares are duly authorized and have been, or upon issuance will be,
validly issued and are fully paid and nonassessable. As of the date hereof, [●] shares of Common Stock are (A) reserved for issuance
pursuant to Convertible Securities (other than the Notes and the Warrants) and (B) owned by Persons who are “affiliates”
(as defined in Rule 405 of the 1933 Act and calculated based on the assumption that only officers, directors and holders of at least
10% of TYDE’s issued and outstanding Common Stock are “affiliates” without conceding that any such Persons are “affiliates”
for purposes of federal securities laws) of TYDE or any of its Subsidiaries. To TYDE’s knowledge, no Person owns 10% or more of
TYDE’s issued and outstanding shares of Common Stock (calculated based on the assumption that all Convertible Securities, whether
or not presently exercisable or convertible, have been fully exercised or converted (as the case may be) taking account of any limitations
on exercise or conversion (including “blockers”) contained therein without conceding that such identified Person is a 10%
stockholder for purposes of federal securities laws).

 

(4) Existing
Securities; Obligations. Except as disclosed in TYDE’s public filings, (A) none of TYDE’s or any Subsidiary’s shares,
interests or capital stock is subject to preemptive rights or any other similar rights or Liens suffered or permitted by TYDE or any
Subsidiary; (B) there are no outstanding options, warrants, scrip, rights to subscribe to, calls or commitments of any character whatsoever
relating to, or securities or rights convertible into, or exercisable or exchangeable for, any shares, interests or capital stock of
TYDE or any of its Subsidiaries, or contracts, commitments, understandings or arrangements by which TYDE or any of its Subsidiaries is
or may become bound to issue additional shares, interests or capital stock of TYDE or any of its Subsidiaries or options, warrants, scrip,
rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities or rights convertible into, or exercisable
or exchangeable for, any shares, interests or capital stock of TYDE or any of its Subsidiaries; (C) there are no agreements or arrangements
under which TYDE or any of its Subsidiaries is obligated to register the sale of any of their securities under the 1933 Act (except pursuant
to the RRA); (D) there are no outstanding securities or instruments of TYDE or any of its Subsidiaries which contain any repurchase or
similar provisions, and there are no contracts, commitments, understandings or arrangements by which TYDE or any of its Subsidiaries
is or may become bound to redeem a security of TYDE or any of its Subsidiaries; ; and (E) neither TYDE nor any Subsidiary has any stock
appreciation rights or “phantom stock” plans or agreements or any similar plan or agreement.

 

    	12

    	 

    

 

(5) Anti-Dilution.
Other than those certain warrants to purchase shares of Common Stock issued to BHP Capital NY, Inc. pursuant to the Securities Purchase
Agreement dated January 26, 2022 between TYDE and BHP Capital NY, Inc., there are no securities or instruments containing anti-dilution
or similar provisions that will be triggered by the transactions contemplated herein.

 

(6) Organizational
Documents. TYDE has furnished to the Holder true, correct and complete copies of TYDE’s Articles of Incorporation, as amended
and as in effect on the date hereof, and TYDE’s bylaws, as amended and as in effect on the date hereof, and the terms of all Convertible
Securities and the material rights of the holders thereof in respect thereto.

 

(xiii) Effectiveness.
TYDE has prepared and filed the Registration Statement in conformity with the requirements of the 1933 Act, which became effective on
June 22, 2022, including the final prospectus filed for the Registration Statement pursuant to Rule 424(b)(3) (the “Prospectus”),
and such amendments and supplements thereto as may have been required to the date of this Agreement. The Registration Statement is effective
under the 1933 Act and does not contain or represent an untrue statement of a material fact or omit to state a material fact necessary
in order to make the statements therein, in the light of the circumstances under which they were made, misleading. No stop order preventing
or suspending the effectiveness of the Registration Statement or suspending or preventing the use of the Prospectus has been issued by
the SEC and no proceedings for that purpose have been instituted or, to the knowledge of TYDE, are threatened by the TYDE.

 

(xiv) Placement
Agent’s and Advisor’s Fees. TYDE has not paid or incurred, and will not pay or incur, any brokerage or finder’s
fees or commissions other financial advisory fees with respect to the transactions contemplated by this Agreement and the other Amendment
Documents payable in cash.

 

 7. CONDITIONS TO TYDE’S OBLIGATIONs hereunder.

 

The
obligations of TYDE to the Holder hereunder are subject to the satisfaction of each of the following conditions, provided that these
conditions are for TYDE’s sole benefit and may be waived by TYDE at any time in its sole discretion by providing the Holder with
prior written notice thereof:

 

(a) The
Holder shall have duly executed this Agreement and delivered the same to TYDE; and

 

(b) The
representations and warranties of the Holder shall be true and correct as of the date when made and as of the Closing Date as though
made at that time (except for representations and warranties that speak as of a specific date which shall be true and correct as of such
specified date), and the Holder shall have performed, satisfied and complied with the covenants, agreements and conditions required by
this Agreement to be performed, satisfied or complied with by the Holder at or prior to the Closing Date.

 

    	13

    	 

    

 

 8. CONDITIONS TO HOLDER’S OBLIGATIONs HEREUNDER.

 

The
obligations of the Holder hereunder are subject to the satisfaction of each of the following conditions, provided that these conditions
are for the Holder’s sole benefit and may be waived by the Holder in respect of itself at any time in its sole discretion by providing
TYDE with prior written notice thereof:

 

(a) TYDE
shall have duly executed and delivered this Agreement to the Holder;

 

(b) The
representations and warranties of each of TYDE under this Agreement shall be true and correct in all respects as of the date when made
and as of the Closing Date as though made at that time (except for representations and warranties that speak as of a specific date which
shall be true and correct as of such specified date) and TYDE shall have performed, satisfied and complied in all respects with the covenants,
agreements and conditions required by this Agreement to be performed, satisfied or complied with by TYDE at or prior to the Closing Date;

 

(c) TYDE
shall have obtained all governmental, regulatory or third party consents and approvals, if any, necessary for the transactions contemplated
hereby; and

 

(d) Since
the date hereof, no event that could be reasonably expected to cause a Material Adverse Effect with respect to TYDE shall have occurred.

 

 9. TERMINATION.

 

In
the event that the Closing shall not have occurred by on or before August 3, 2022, other than due to the Holder’s failure to satisfy
the conditions set forth in Section 7 hereof, the Holder shall have the option to terminate this Agreement at the close of business on
such date without liability of any party to any other party. Upon such termination, the terms hereof shall be null and void.

 

 10. MISCELLANEOUS.

 

(a) Governing
Law; Jurisdiction; Jury Trial. All questions concerning the construction, validity, enforcement and interpretation of this Agreement
shall be governed by the internal laws of the State of New York, without giving effect to any choice of law or conflict of law provision
or rule (whether of the State of New York or any other jurisdictions) that would cause the application of the laws of any jurisdictions
other than the State of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts
sitting in The City of New York, Borough of Manhattan, for the adjudication of any dispute hereunder or in connection herewith or with
any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action
or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding
is brought in an inconvenient forum or that the venue of such suit, action or proceeding is improper. Each party hereby irrevocably waives
personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof to
such party at the address for such notices to it under this Agreement and agrees that such service shall constitute good and sufficient
service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any
manner permitted by law. EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE
ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION WITH OR ARISING OUT OF THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY.

 

    	14

    	 

    

 

(b) Counterparts.
This Agreement may be executed in two or more identical counterparts, all of which shall be considered one and the same agreement and
shall become effective when counterparts have been signed by each party and delivered to the other party; provided that a facsimile signature
shall be considered due execution and shall be binding upon the signatory thereto with the same force and effect as if the signature
were an original, not a facsimile signature.

 

(c) Headings.
The headings of this Agreement are for convenience of reference and shall not form part of, or affect the interpretation of, this Agreement.

 

(d) Severability.
If any provision of this Agreement is prohibited by law or otherwise determined to be invalid or unenforceable by a court of competent
jurisdiction, the provision that would otherwise be prohibited, invalid or unenforceable shall be deemed amended to apply to the broadest
extent that it would be valid and enforceable, and the invalidity or unenforceability of such provision shall not affect the validity
of the remaining provisions of this Agreement so long as this Agreement as so modified continues to express, without material change,
the original intentions of the parties as to the subject matter hereof and the prohibited nature, invalidity or unenforceability of the
provision(s) in question does not substantially impair the respective expectations or reciprocal obligations of the parties or the practical
realization of the benefits that would otherwise be conferred upon the parties. The parties will endeavor in good faith negotiations
to replace the prohibited, invalid or unenforceable provision(s) with a valid provision(s), the effect of which comes as close as possible
to that of the prohibited, invalid or unenforceable provision(s).

 

(e) Entire
Agreement; Amendments. This Agreement shall supersede all other prior oral or written agreements among the Holder and TYDE, their
Affiliates and persons acting on their behalf with respect to the matters discussed herein and therein, and this Agreement, and the instruments
referenced herein contain the entire understanding of the parties with respect to the matters covered herein and therein. No provision
of this Agreement may be amended other than by an instrument in writing signed by TYDE and the Holder, and any amendment to this Agreement
made in conformity with the provisions of this Section 10(e) shall be binding on the Holder and TYDE. No provision hereof may be waived
other than by an instrument in writing signed by the party against whom enforcement is sought.

 

    	15

    	 

    

 

(f) Notices.
Any notices, consents, waivers or other communications required or permitted to be given under the terms of this Agreement must be in
writing and will be deemed to have been delivered: (i) upon receipt, when delivered personally; (ii) upon receipt, when sent by facsimile
(provided confirmation of transmission is mechanically or electronically generated and kept on file by the sending party) or electronic
mail (provided that such sent email is kept on file (whether electronically or otherwise) by the sending party and the sending party
does not receive an automatically generated message from the recipient’s email server that such e-mail could not be delivered to
such recipient); or (iii) three (3) business days after deposit with an overnight courier service with next day delivery specified, in
each case, properly addressed to the party to receive the same. The addresses, facsimile numbers and e-mail addresses for such communications
shall be:

 

If
to TYDE:

 

Cryptyde,
Inc.

200
9th Avenue North, Suite 220

Safety
Harbor, Florida 34695

Telephone:
(866) 980-2818

Attention:
Chief Executive Officer

E-Mail:
BPM@cryptyde.com

 

With
a copy (for informational purposes only) to:

 

Haynes
Boone LLP

2323
Victory Avenue, Suite 700

Dallas,
TX 75219

Telephone:
(214)651-5119

Attention:
W. Bruce Newsome, Esq.

E-Mail:
Bruce.Newsome@haynesboone.com

 

If
to the Holder, to its address, e-mail address and facsimile number set forth on the signature pages attached hereto, with copies to the
Holder’s representatives as set forth on such Holder’s signature page, or to such other address, e-mail address and/or facsimile
number and/or to the attention of such other Person as the recipient party has specified by written notice given to each other party
five (5) days prior to the effectiveness of such change, provided that Schulte Roth & Zabel LLP shall only be provided copies of
notices sent to the Holder. Written confirmation of receipt (A) given by the recipient of such notice, consent, waiver or other communication,
(B) mechanically or electronically generated by the sender’s facsimile machine or e-mail containing the time, date, recipient facsimile
number and, with respect to each facsimile transmission, an image of the first page of such transmission or (C) provided by an overnight
courier service shall be rebuttable evidence of personal service, receipt by facsimile or receipt from an overnight courier service in
accordance with clause (i), (ii) or (iii) above, respectively.

 

(g) Successors
and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their respective successors and assigns,
including any purchasers of the Exercised Warrants.

 

(h) No
Third Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective permitted successors
and assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other Person.

 

    	16

    	 

    

 

(i) Survival.
The representations, warranties and covenants of TYDE and the Holder contained herein shall survive the Closing.

 

(j) Further
Assurances. Each party shall do and perform, or cause to be done and performed, all such further acts and things, and shall execute
and deliver all such other agreements, certificates, instruments and documents, as any other party may reasonably request in order to
carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby.

 

(k) No
Strict Construction. The language used in this Agreement will be deemed to be the language chosen by the parties to express their
mutual intent, and no rules of strict construction will be applied against any party.

 

(l) Fees
and Expenses. TYDE shall reimburse the Holder for its legal fees and expenses in connection with the preparation and negotiation
of this Agreement and transactions contemplated thereby, by paying any such amount to Schulte Roth & Zabel LLP (the “Holder
Counsel Expense”) within two (2) Business Days of receiving the invoice of Schulte Roth & Zabel LLP by wire transfer of
immediately available funds in accordance with the written instructions of Schulte Roth & Zabel LLP delivered to TYDE on or prior
to the Closing. The Holder Counsel Expense shall be paid by TYDE whether or not the transactions contemplated by this Agreement are consummated.
Except as otherwise set forth above, each party shall pay the fees and expenses of its advisers, counsel, accountants and other experts,
if any, and all other expenses incurred by such party incident to the negotiation, preparation, execution, delivery and performance of
this Agreement. TYDE shall pay all stamp and other taxes and duties levied in connection with the transactions contemplated hereby, if
any.

 

[Signature
Page Follows]

 

    	17

    	 

    

 

IN
WITNESS WHEREOF, the Holder and TYDE have caused their respective signature pages to this Agreement to be duly executed as of the
date first written above.

 

	 	TYDE:
	 	 
	 	CRYPTYDE,
    INC.
	 	 	 
	 	By:	/s/
    Brian McFadden
	 	Name:	Brian
    McFadden
	 	Title:
    	Chief
    Executive Officer

 

[Signature Page to Amendment Agreement]

 

    	 

    	 

    

 

IN
WITNESS WHEREOF, the Holder and TYDE have caused their respective signature pages to this Agreement to be duly executed as of the
date first written above.

 

	 	HOLDER:
	 	 
	 	HUDSON
    BAY MASTER FUND LTD.
	 	 	 
	 	By:	/s/
    Richard Allison
	 	Name:	Richard
    Allison
	 	Title:
    	Authorized
    Signatory*

 

	 	Contact
    Information for Notices:
	 	 	 
	 	Attention:
    	 
	 	Facsimile:	 
	 	Telephone:
    	 
	 	Residence:
    	 
	 	E-mail:
    	 
	 	 	 
	 	with
    a copy (for informational purposes only) to:
	 	 	 
	 	Telephone:	 
	 	Facsimile:	 
	 	Attention:	 
	 	E-mail:	 
	 	 	 
	Wire instruction for delivery of Company Repurchase Amount:
	 	 	 
		 	 
	 	 	 
		 	 
	 	 	 
		 	 

 

	*Authorized Signatory

    Hudson Bay Capital Management LP not individually, but solely as Investment Advisor to Hudson Bay Master Fund Ltd

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00346-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00346-of-00352.parquet"}]]